inflammatory syndrome in children (MIS-C)

Title: A distinct cross-reactive autoimmune response in multisystem 1 2 3 Authors: Aaron Bodansky¹, Joseph J. Sabatino, Jr.^{2,3}, Sara E. Vazquez⁴, Janet Chou^{5,6}, Tanya 4 Novak^{7,8}, Kristin L. Moffitt^{6,9}, Haleigh S. Miller^{4,10}, Andrew F. Kung^{4,10}, Elze Rackaityte⁴, Colin R. Zamecnik^{2,3}, Jayant V. Rajan⁴, Hannah Kortbawi^{4,11}, Caleigh Mandel-Brehm⁴, Anthea Mitchell¹², Chung-Yu Wang¹², Aditi Saxena¹², Kelsey Zorn⁴, David J.L. Yu¹³, James Asaki¹⁴, 5 6 7 John V. Pluvinage³, Michael R. Wilson^{2,3}; Laura L. Loftis¹⁵, Charlotte V. Hobbs¹⁶, Keiko M. 8 Tarquinio¹⁷, Michele Kong¹⁸, Julie C. Fitzgerald¹⁹, Paula S. Espinal²⁰, Tracie C. Walker²¹, 9 Stephanie P. Schwartz²¹, Hillary Crandall²², Katherine Irby²³, Mary Allen Staat²⁴, Courtney M. 10 Rowan²⁵, Jennifer E. Schuster²⁶, Natasha B. Halasa²⁷, Shira J. Gertz²⁸, Elizabeth H. Mack²⁹, 11 Aline B. Maddux³⁰, Natalie Z. Cvijanovich³¹, Matt S. Zinter¹, Laura D. Zambrano³², Angela P. 12 Campbell³², Adrienne G. Randolph^{6,7,8}†, Mark S. Anderson¹³†*, Joseph L. DeRisi¹²†*; and the 13 14

Affiliations: 15

¹ Department of Pediatrics, Division of Critical Care, University of California San Francisco, 16 17 San Francisco, CA

Overcoming COVID-19 Network Study Group Investigators³³

- ²Weill Institute for Neurosciences, University of California San Francisco; San Francisco, 18 19 CA
- ³ Department of Neurology, University of California San Francisco; San Francisco, CA 20
- ⁴ Department of Biochemistry and Biophysics, University of California San Francisco, San 21 Francisco, CA 22
- ⁵ Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, 23 MA 24
- ⁶ Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, 25 MA 26
- ⁷ Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's 27 Hospital, Boston, MA 28
- ⁸ Department of Anesthesia, Harvard Medical School, Boston, MA. 29
- ⁹ Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA 30
- ¹⁰ Biological and Medical Informatics Program, University of California San Francisco, San 31 Francisco, CA USA 32
- ¹¹ Medical Scientist Training Program, University of California San Francisco, San 33 Francisco, CA 34
- ¹²Chan-Zuckerberg Biohub, San Francisco, CA 35
- ¹³ Diabetes Center, School of Medicine, University of California San Francisco, San 36
- Francisco, CA. 37
- ¹⁴ Biomedical Sciences Program, University of California San Francisco, San Francisco, CA. 38

39 40	¹⁵ Division of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
41 42	¹⁶ Department of Pediatrics, Division of Infectious Diseases, Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS.
43 44	¹⁷ Division of Critical Care Medicine, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA
45 46	¹⁸ Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL
47 48	¹⁹ Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.
49 50	²⁰ Personalized Medicine and Health Outcomes Research, Nicklaus Children's Hospital, Miami, FL
51 52	²¹ Department of Pediatrics, University of North Carolina at Chapel Hill Children's Hospital, Chapel Hill, NC.
53 54	²² Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, Primary Children's Hospital, Salt Lake City, UT
55 56	²³ Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Children's Hospital, Little Rock, AR
57 58	²⁴ Department of Pediatrics, University of Cincinnati, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
59 60	²⁵ Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN.
61 62	²⁶ Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO.
63 64	²⁷ Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN
65 66	²⁸ Division of Pediatric Critical Care, Department of Pediatrics, Cooperman Barnabas Medical Center, Livingston, NJ
67 68	²⁹ Division of Pediatric Critical Care Medicine, Medical University of South Carolina, Charleston, SC
69 70	³⁰ Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO
71	³¹ Division of Critical Care Medicine, UCSF Benioff Children's Hospital Oakland, CA
72 73	³² COVID-19 Response Team and Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA.
74 75	³³ Overcoming COVID-19 Network Study Group Investigators: full list of the authors and affiliations at the end of the main manuscript.
76	*Corresponding authors. Email: mark.anderson@ucsf.edu and joe@derisilab.ucsf.edu

- ⁷⁷ [†] These authors contributed equally to this work
- 78
- 79 Abstract: Multisystem inflammatory syndrome in children (MIS-C) is a severe, post-infectious
- sequela of SARS-CoV-2 infection, yet the pathophysiological mechanism connecting the
- infection to the broad inflammatory syndrome remains unknown. Here we leveraged a large set
- of MIS-C patient samples (n=199) to identify a distinct set of host proteins that are differentially
- targeted by patient autoantibodies relative to matched controls. We identified an autoreactive
- 84 epitope within SNX8, a protein expressed primarily in immune cells which regulates an antiviral
- pathway associated with MIS-C pathogenesis. In parallel, we also probed the SARS-CoV-2
- ⁸⁶ proteome-wide MIS-C patient antibody response and found it to be differentially reactive to a
- distinct domain of the SARS-CoV-2 nucleocapsid (N) protein relative to controls. This viral N
- region and the mapped SNX8 epitope bear remarkable biochemical similarity. Furthermore, we
- find that many children with anti-SNX8 autoantibodies also have T-cells cross-reactive to both
- 90 SNX8 and this distinct domain of the SARS-CoV-2 N protein. Together, these findings suggest
- 91 that MIS-C patients develop a distinct immune response against the SARS-CoV-2 N protein that
- is associated with cross reactivity to the self-protein SNX8, demonstrating a link from the
- 93 infection to the inflammatory syndrome.

Introduction: 94

- 95 Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to a
- broad spectrum of disease (1-3). The course of disease in children is often mild (4-6) but can 96
- 97 become severe due to a variety of known (7, 8) and yet-to-be discovered factors. In rare cases
- children develop multisystem inflammatory syndrome in children (MIS-C), a post-infectious 98
- complication which often results in critical illness (9-11). The disease was hypothesized to be 99
- related to Kawasaki Disease, which presents similarly with prolonged fever, systemic 100
- inflammation, rash, conjunctivitis, and can be complicated by myocarditis and coronary artery 101
- aneurysms. In contrast to Kawasaki Disease, however, MIS-C is temporally associated after a 102
- SARS-CoV-2 infection, and more commonly includes shock, cardiac dysfunction, and multi-103
- organ system involvement including gastrointestinal symptoms and hematologic findings, such 104
- as thrombocytopenia and lymphopenia (13–17). Through extensive characterization, MIS-C has 105
- been shown to have a distinctive inflammatory and cytokine signature, with evidence of altered 106
- innate and adaptive immunity as well as autoimmunity(17–23). 107
- 108
- While the pathophysiological link between SARS-CoV-2 and MIS-C remains enigmatic, other 109
- 110 autoimmune diseases are the consequence of exposure to novel antigens in the form of a virus or
- oncoprotein. For example, multiple sclerosis is associated with Epstein-Barr-Virus infection, and 111
- recent data suggests that B-cells and T-cells which are cross-reactive between a viral protein 112
- 113 (EBNA1) and several host proteins may contribute to disease development(24-26). In addition,
- decades of paraneoplastic autoimmune encephalitis research, including anti-Hu, anti-Yo, anti-114
- kelch-like protein 11, and many others, highlight the importance of autoreactive B-cells and T-115
- cells working in concert to cause disease by targeting a shared intracellular antigen, and in 116
- certain cases a shared epitope (28-35). 117
- 118
- 119 Though cross-reactivity has not yet been identified in MIS-C, multiple autoantibodies have been
- reported (20–22), including those targeting interlueukin-1 receptor antagonist (IL-1Ra) (35). 120
- Distinctive T-cell signatures have also been reported in MIS-C, including an expansion of 121
- TRVB11-2 T-cells(23, 36–39) accompanied by autoimmune-associated B-cell expansions(21). 122
- Because the T-cell expansion is not monoclonal, many have speculated that a yet-to-be-identified 123
- superantigen is responsible. However, recent experiments suggest the expansion may instead by 124
- the result of activated tissue-resident T-cells(41), though the antigenic target of these T-cells 125
- remains unknown. Altered innate immune function has also been implicated in a subset of MIS-126
- C cases, including inborn errors of immunity involving regulation of the mitochondrial antiviral-127
- signaling (MAVS) protein pathway (41). 128
- 129
- Here, children previously infected with SARS-CoV-2- with (n=199) and without (n=45) MIS-C 130
- were enrolled and comprehensively profiled for autoreactive antibodies as well as those targeting 131
- 132 SARS-CoV-2. Differential autoreactivity highlighted an epitope motif which is shared by the
- viral N protein and the human SNX8 protein. SNX8 is expressed by immune cells across 133
- multiple tissues and modulates MAVS activity(43). This cross-reactive epitope motif is targeted
- by both B-cells and T-cells, suggesting that a subset of MIS-C may be triggered by molecular mimicry. 136
- 137 **Results**

MIS-C patients harbor a distinct set of autoreactivities 138

134 135

- 139 To explore the hypothesis that MIS-C is driven by an autoreactive process, the spectrum of
- autoantibody specificities present in children with MIS-C (n=199) and children who had
- asymptomatic or mild SARS-CoV-2 infection without MIS-C (within at least 5 weeks of
- 142 enrollment) (n=45, hereafter referred to as "at-risk controls") was captured using phage
- 143 immunoprecipitation and sequencing (PhIP-Seq)(44). The PhIP-Seq technique has been
- extensively used to identify novel autoantigens in a wide range of diseases, and the specific
- 145 768,000 element human proteome-wide library used in these experiments has been used to define
- novel autoimmune syndromes and markers of disease for a variety of conditions (29, 33, 44-46).
- Given the inherently heterogeneous nature of antibody repertoires among individuals, the
- identification of disease-associated autoreactive antigens requires the use of large numbers of
 cases and controls (45). To minimize spurious hits, this study contains 199 MIS-C cases and 45
- cases and controls (45). To minimize spurious hits, this study contains 199 MIS-C cases and 45
 at-risk controls with recent SARS-CoV-2 infection, which represents substantially more MIS-C
- cases and controls than previously published (Figure 1A)(20-22, 44). Clinical characteristics of
- 152 this cohort are described in Table 1.
- 153

154 **Table 1: Clinical characteristics of MIS-C and at-risk control cohorts.**

	MIS-C	Control
Number	199	45
Male sex (%)	118 (59.3)	24 (53.3)
Median age in years (median, IQR)	10.9 (7.5 - 14.7)	5.5 (2.2 – 11.1)
Race and ethnicity (%)		
White, non-Hispanic	63 (31.7)	14 (31.1)
Black, non-Hispanic	74 (37.2)	5 (11.1)
Hispanic or Latino	47 (23.6)	15 (33.3)
Other race, non-Hispanic	8 (4.0)	2 (4.4)
Unknown	7 (3.5)	9 (20.0)
Underlying conditions (%)		
None	134 (67.3)	36 (80)
Obesity*	29 (15.2)	8 (21.6)
Asthma	22 (11.1)	1 (2.2)
Cardiovascular	4 (2.0)	0 (0.0)
Immunocompromise	0 (0.0)	0 (0.0)
Autoimmune condition	1 (0.5) †	0 (0.0)
Malignancy	1 (0.5)	0 (0.0)
Hospital Course (%)		
ICU admission	170 (85.4)	0 (0.0)
Shock requiring vasopressors	90 (45.2)	0 (0.0)
Mechanical ventilation	38 (19.1)	0 (0.0)
Extracorporeal membrane oxygenation (ECMO)	8 (4.0)	0 (0.0)

*Does not include n=8 MIS-C patients and n=11 controls under 2 years of age.

156 *†*Patient on chronic systemic steroids for eosinophilic esophagitis

157 For any given set of samples, PhIP-Seq has the potential to yield dozens to many thousands of

- differential enrichments of phage-displayed peptides. Here, logistic regression machine learning
- 159 was used to first assess in an unbiased manner whether there existed a set of differentially
- enriched peptides that classify whether a sample is from an MIS-C patient or an at-risk control.
- 161 This approach has been previously used with PhIP-Seq data to accurately classify Autoimmune
- Polyglandular Syndrome Type 1 (APS1) cases from controls (*45*). In this experiment, model input included the enrichments for all recovered peptide sequences derived from each sample.
- The training and classification were iterated 1,000 times using 5-fold cross validation, whereby
- 165 80% of the dataset is randomly chosen for training with the remaining 20% withheld for testing
- the classifier. Examination of the largest logistic regression coefficients associated with MIS-C
- 167 disease revealed significant contributions to the classifier from peptides derived from the ERFL
- 168 (ETS repressor factor like), SNX8 (Sorting nexin 8), and KDELR1 (KDEL endoplasmic
- reticulum protein retention receptor 1) coding sequences, followed by progressively smaller
- contributions from other genes. In all, 107 proteins had LR coefficients greater than zero, thus
- indicating greater autoantibody presence in MIS-C, and referred to here as the *classifier* set
- 172 (Figure 1B). The receiver operating characteristic (ROC) curve for this analysis yielded a narrow
- 173 range of values, with an average area under the curve (AUC) of 0.94 (Figure 1C).
- 174 In parallel, the Kolmogorov-Smirnov (KS) test was used to identify 661 statistically enriched
- autoreactivities (*statistically enriched set*: those with a p-value after adjustment for multiple test
- false discovery rates (FDR) less than 0.01). There is no agreed upon way to identify the most
- 177 likely putative autoantibodies associated with disease among large peptidomic datasets. To avoid
- false positives, the intersection (n=35) of the *classifier* set and the *statistically enriched* set were
- considered further. Of these, peptides derived from 30 different genes also satisfied an additional
- 180 set of conservative criteria, requiring that none be enriched (Fold-change over mock-IP (FC)>3)
- in more than a single control, or be enriched greater than 10-fold in any number of controls,
- hereafter referred to as the *MIS-C Set* (Figure 1B, Figure 1D). These 30 genes code for proteins
- 183 with diverse function and tissue expression.
- 184

185 Previously reported MIS-C autoantibodies

- 186 Approximately 34 candidate autoantigens have been previously reported as associated with MIS-
- 187 C (20–22, 44). Of these, 33 were present in a similar proportion of MIS-C cases and at-risk
- controls in this cohort (Supplemental Figure 1A). Autoantibodies targeting the ubiquitously
- 189 expressed ubiquitin protein ligase UBE3A were independently identified in this study as part of
- both the *classifier set* and the *statistically enriched set*, but we did not include them in the *MIS-C*
- 191 Set given low positive signal in 2 controls.
- 192
- Additionally, autoantibodies to the receptor antagonist IL-1Ra were previously reported in 13 of
- 194 21 (62%) MIS-C patients(35). In this cohort, anti-IL-1Ra antibodies were detected by PhIP-Seq
- (z-score > 6 over at-risk control) in 6 patient samples. To further examine immune reactivity to
- 196 full length IL-1Ra, samples from 196 of the 199 patients in this study were used to
- 197 immunoprecipitate S35 radiolabeled IL-1Ra (Methods). Positive immunoprecipitation of IL-1Ra
- 198 (defined as greater than 3 standard deviations above mean of controls) was found in 39/196
- (19.9%) patients with MIS-C, and the overall signal was significantly increased relative to at-risk
- 200 controls (p-value <0.0001). However, many MIS-C patients were treated with intravenous
- 201 immunoglobulin (IVIG), a blood product that has been shown to have autoantibodies(48). After
- 202 removing samples of MIS-C patients who were treated with IVIG prior to sample collection (61

remaining), the difference between samples from MIS-C patients (5/61, 8.2%) and at-risk

controls (1/45, 2.2%) was not significant (p-value = 0.30) (Supplemental Figure 1B).

205

206 MIS-C autoantigens lack tissue specific associations with clinical phenotypes

207 Consistent with previous MIS-C reports(10, 18), this cohort was clinically heterogenous

- 208 (Supplemental Table 1). To determine whether specific phenotypes, including myocarditis and
- the requirement of vasopressors, might be associated with specific autoantigens present in the
- 210 MIS-C Set, protein tissue expression levels were assigned to each autoantigen (Human Protein
- Atlas; Proteinatlas.org), including amount of expression in cardiomyocytes and cardiac
- 212 endothelium. The PhIP-Seq signal for MIS-C patients with a particular phenotype was compared
- to those MIS-C patients without the phenotype. Autoantigens with tissue specificity were not
- 214 enriched in those MIS-C patients with phenotypes involving said tissue. Similarly, those
- autoantigens associated with myocarditis or vasopressor requirements did not correlate with
- 216 increased cardiac expression (Supplemental Figure 2).
- 217

218 Orthogonal validation of PhIP-Seq autoantigens

- 219 Peptides derived from ERFL, SNX8, and KDELR1 carried the largest logistic regression
- 220 coefficients in the MIS-C classifier. The PhIP-Seq results were orthogonally confirmed by
- immunoprecipitation of S35 radiolabeled full-length ERFL, SNX8, and KDELR1 (radioligand
- binding assay (RLBA), see Methods) with patient (196 of the 199 samples used for PhIP-Seq)
- and at-risk control (all 45) samples. Relative to at-risk controls, samples from MIS-C patients
- significantly enriched each of the three target proteins (p-value <0.00000001 for ERFL, SNX8,
- and KDELR1), consistent with the PhIP-Seq assay (Figure 1E). Using only the radiolabeled
- immunoprecipitation data for these three proteins, MIS-C could be confidently classified (using
- 5-fold cross validation, iterated 1,000 times) from at-risk control sera with a ROC AUC of 0.93,
- suggesting potential for molecular diagnostic purposes (Figure 1F).
- 229

In this cohort, IVIG was administered to 137 of the 199 patients with MIS-C prior to sample

- collection and was absent from all 45 at-risk controls. The autoreactivity to the ERFL, SNX8,
- and KDELR1 proteins from the 62 MIS-C patients who had not been treated with IVIG prior to
- sample collection were compared to the at-risk controls (Supplemental Figure 3A). In contrast to
- IL-1Ra, the differential enrichment of these three proteins remained significant (p-value <0.0001,
- 235 <0.00007, and <0.00011 respectively) suggesting that autoreactivity to ERFL, SNX8, and
- KDELR1 proteins was not confounded by IVIG treatment (Supplemental Figure 3B).
- 237
- 238

239 Independent MIS-C cohort validation

- 240 To further test the validity of these findings, an independent validation cohort consisting of
- samples from 24 different MIS-C patients and 29 children severely ill with acute COVID-19
- infection was acquired (Supplemental Table 2). Using the RLBA assay with full length SNX8,
- ERFL, and KDELR1 proteins, all three target proteins were significantly enriched relative to
- both the at-risk controls (p-value = 0.00023, 0.00004, and 0.00003 for ERFL, SNX8, and
- KDELR1, respectively) and the severe acute COVID-19 patients (p-value = 0.007, 0.008, 0.0012
- for ERFL, SNX8, and KDELR1, respectively) (Supplemental Figure 4A). Using a logistic
- regression classifier that was trained on the original cohort, the ROC AUC in the validation
- cohort for classification of MIS-C from at-risk controls was 0.84, and from severe acute pediatric

249 COVID-19 was 0.78 (Supplemental Figure 4B), suggesting that autoreactivity to these three

250 proteins is a significant feature of MIS-C separable not only from SARS-CoV-2 exposure itself,

- but also from severe acute pediatric COVID-19.
- 252

253 MIS-C autoantibodies target a single epitope within SNX8 protein

SNX8 is a protein of 465 amino acids that belongs to a family of sorting nexins involved in 254 endocytosis, endosomal sorting, and signaling(49). Publicly available expression data (Human 255 Protein Atlas; Proteinatlas.org) shows SNX8 is widely expressed across a variety of tissues 256 including the brain, heart, gastrointestinal tract, kidneys, and skin, with highest expression in 257 undifferentiated cells and immune cells. Previous work has associated SNX8 with host defense 258 against bacteria, DNA viruses, and RNA viruses (43, 50, 51). ERFL is a poorly characterized 259 protein of 354 amino acids. A survey of single cell RNA sequencing data (Human Protein Atlas; 260 Proteinatlas.org) suggests enrichment in plasma cells, B-cells, and T-cells in some tissues. Using 261 a Spearman correlation in principal component analysis (PCA) space based on tissue RNA 262 sequencing data (Human Protein Atlas; Proteinatlas.org) SNX8 has the second closest expression 263 pattern to ERFL, with a correlation of 0.81. KDELR1 is a 212 amino acid ER-Golgi transport 264 265 protein essential to lymphocyte development with low tissue expression specificity. All three proteins are predicted or known to be intracellular, suggesting that putative autoantibodies 266 targeting these proteins are unlikely to be sufficient for disease pathology on their own. 267 268 However, autoantibodies targeting intracellular antigens are often accompanied by a T-cell which is autoreactive to the protein from which that antigen was derived, and which targets cell 269 types expressing the protein. Of these proteins, we selected SNX8 for further investigation given 270

- its enrichment in immune cells, as well as its putative role in regulating the MAVS pathway in
- response to RNA viral infection, a pathway recently implicated in MIS-C pathology(41).
- 273

Full length SNX8 is represented in this PhIP-Seq library by 19 overlapping 49mer peptides. For

all but one patient sample, the peptide fragment spanning amino acid positions 25 to 73 was the most enriched in the PhIP-Seq assay (Figure 2A), suggesting a common autoreactive site. To

narrow the portion of this peptide to a smaller fragment, a sequential alanine scan was performed

(Figure 2B; Methods). Using samples from six individuals with MIS-C, the critical region for

immunoreactivity was determined to span 9 amino acids, positions 51 through 59

280 (PSRMQMPQG). Using the wild-type 49 amino acid peptide and the version with the critical

region mutated to alanines, 182 of the 199 MIS-C patients and all 45 controls were assessed for

immunoreactivity using a split-luciferase binding assay (Methods; SLBA). We found that

samples from 31 of 182 (17.0%) patients with MIS-C immunoprecipitated the wildtype

fragment. Of these, 29 (93.5%) failed to immunoprecipitate the mutated peptide, suggesting a

common shared autoreactive epitope among nearly all of the MIS-C patients with anti-SNX8
 antibodies. In contrast, only a single sample (out of 45) from the at-risk control cohort

antibodies. In contrast, only a single sample (out of 45) from the at-risk control co immunoprecipitated the wildtype fragment in this assay (Supplemental figure 5).

288

289 MIS-C patients have an altered antibody response to the SARS-CoV-2 N protein

290 To evaluate whether differences exist in the humoral immune response to SARS-CoV-2 infection

in patients with MIS-C relative to at-risk controls, we repeated PhIP-Seq with 181 of the original

²⁹² 199 MIS-C patients and all 45 of the at-risk controls using a previously validated library specific

- for SARS-CoV-2(52). To discover whether certain fragments were differentially enriched by
- 294 either MIS-C or at-risk controls, the enrichment of each phage encoded SARS-CoV-2 peptide

(38 amino acids each) in each of the MIS-C patients and each at-risk control was normalized to 295 48 pre-COVID healthy controls. Three nearly adjacent peptides derived from the SARS-CoV-2 296 N protein were found to have significant differences in enrichment (KS-test, p< 0.000001 for 297 298 each of the three peptides). The first peptide, spanning amino acids 77-114, was significantly enriched in the at-risk controls (representing the typical serological response in children), 299 whereas the next two fragments, spanning amino acids 134-190, were significantly enriched by 300 MIS-C patients (Figure 3A, B). This differentially reactive domain of the SARS-CoV-2 N 301 protein was termed the MIS-C associated domain of SARS-CoV-2 (MADS). The PhIP-Seq 302 results were orthogonally confirmed using the SLBA assay to measure the amount of MADS 303 peptide immunoprecipitated with samples from 16 individuals, including 11 MIS-C patients and 304 5 at-risk controls (Figure 3C). To more precisely map the critical reactive region of the 305 differentially enriched N protein peptides by MIS-C samples, peptides featuring a sliding 306 window of 10 alanine residues were used as the immunoprecipitation substrate for the SLBA 307 assay, run in parallel with the SNX8 alanine scanning peptides for three MIS-C sera samples 308 (Figure 3D). Remarkably, the critical regions identified here in both SNX8 and SARS-CoV-2 N 309

- protein possessed significant similarity and can be represented by the regular expression [ML]Q[ML]PQG (Figure 3E).
- 312

313 MIS-C patients have significantly increased SNX8 autoreactive T-cells

In other autoimmune diseases, autoantibodies are often generated against intracellular targets, yet 314 the final effectors of cellular destruction are autoreactive T-cells(31, 52). Given evidence that 315 certain subsets of MIS-C are HLA-associated(36, 37), and that SNX8 is known to be an 316 intracellular protein, we hypothesized that MIS-C patients with anti-SNX8 antibodies may, in 317 addition to possessing SNX8 autoreactive B-cells, also possess autoreactive T-cells targeting 318 SNX8 expressing cells. To test this hypothesis, T-cells from 9 MIS-C patients (8 from SNX8 319 320 autoantibody positive patients and 1 who was SNX8 autoantibody negative) and 10 at-risk controls (chosen randomly) were exposed to a pool of 15-mer peptides with 11 amino acid 321 overlaps that collectively tiled full length human SNX8 protein. T-cell activation was measured 322 by an activation induced marker (AIM) assay, which quantifies upregulation of three cell 323 activation markers: OX40, CD69 and CD137 (Figure 4A)(53-55). The percent of T-cells which 324 activated in response to SNX8 protein was significantly higher in MIS-C than controls (p-value 325 <0.001) Using a positive cutoff of 3 standard deviations above the mean of the controls, 7 of the 326 9 MIS-C (78%) patients were deemed positive for SNX8 autoreactive T-cells, while no controls 327 met these criteria (Figure 4B). With respect to CD8+ and CD4+ subgroups specifically, there 328 was increased signal in MIS-C relative to controls which did not meet significance (p=0.071 and 329 p=0.058, respectively) (Supplemental Figure 6). The MIS-C patient who was seronegative for 330 the SNX8 autoantibody was also negative for SNX8 autoreactive T-cells. 331

332

333 HLA type A*02 is more likely to present the shared epitope

MIS-C has been associated with HLA types A*02, B*35, and C*04(36, 37). The Immune

Epitope Database and Analysis Resource (IEDB.org(56)) was used to rank the MHC1 peptide

presentation likelihoods for both SNX8 and SARS-CoV-2 N protein with respect to the MIS-C

associated HLA alleles. The distribution of predicted MHC I binding scores for N protein and

338 SNX8 fragments matching the [ML]Q[ML]PQG regular expression relative to fragments lacking

a match was compared. For HLA type A*02, predicted MHC I binding was significantly higher

340 (p<0.0001 for N protein and p=0.001 for SNX8) for fragments containing the putative

autoreactive motif. There was no statistical difference for HLA B*35 and C*04 predictions

342 (Supplemental Figure 7). Of note, of the 7 MIS-C patients with SNX8 autoreactive T-cells, 4 of

the patients had HLA-typing performed, and all 4 were HLA-A*02 positive (Supplemental
Figure 6).

345

346 Identification of MIS-C T-cells cross-reactive to the similarity regions of SNX8 and N protein

Given the prediction that MIS-C associated HLA types preferentially display peptides containing

the similarity regions for both SNX8 and the SARS-CoV-2 N protein, we sought to determine

- whether cross-reactive T-cells were present, and if they were specific to MIS-C. We therefore
- stimulated PBMCs from 3 MIS-C patients and 3 at-risk controls with peptides from either the
- SNX8 similarity region [MQMPQGNPL] or the SARS-CoV-2 N protein similarity region
 [LQLPQGITL] for 7 days to enrich for CD8+ T-cells reactive to these epitopes. We then built
- [LQLPQGITL] for 7 days to enrich for CD8+ T-cells reactive to these epitopes. We then built
 differently labeled MHCI tetramers loaded with either the SNX8 peptide [MQMPQGNPL] or the
- 354 SARS-CoV-2 peptide [LQLPQGITL] (Figure 4C) and measured binding to T-cells.
- 355

Each of the three MIS-C patients had multiple CD8+ T-cells which bound to both the SNX8

357 peptide and the SARS-CoV-2 peptide. None of the three at-risk controls had any cross-reactive

358 CD8+ T-cells. The percentage of CD8+ T-cells binding to each of the individual epitopes was

also measured (Figure 4D). The 3 MIS-C patients had multiple T-cells which bound to the N

360 protein peptide, SNX8 peptide, and both peptides (cross-reactive).

361

362 SNX8 peptide with similarity region is sufficient to activate T-cells

Because MIS-C patients preferentially harbor T-cells which activate in response to a peptide 363 pool containing fragments spanning the entire SNX8 protein and have T-cells which are cross-364 reactive T-cells between similarity regions of SNX8 and the N-protein, the similarity region of 365 SNX8 alone was tested for its ability to activate patient T-cells. A pool of 20 10mer peptides 366 with 9 amino acid overlaps centered on the target motif from SNX8 (collectively spanning amino 367 acids 44 through 72) was used to stimulate PBMCs from two patients with MIS-C and 4 at-risk 368 controls. Both of the MIS-C patients had activation of T-cells and none of the 4 controls had T-369 cell activation (Supplemental figure 8). 370

371

372 RNA expression profile of SNX8 during SARS-CoV-2 infection

As previously discussed, SNX8 is widely expressed across many tissue types, but most highly

expressed by immune cells, consistent with its known function defending against RNA viruses

via recruitment of MAVS(43). To further investigate the potential impact of combined B-cell and

T-cell autoimmunity to SNX8 in the setting of SARS-CoV-2 infection, we analyzed SNX8

expression from single-cell sequencing of PBMC samples from patients with severe, mild, or

asymptomatic COVID-19 infection, influenza infection, and uninfected healthy controls (57).

In the setting of SARS-CoV-2 infection, SNX8 has highest mean expression in classical and

- non-classical monocytes and B-cells (Supplemental Figure 9A and Supplemental Figure 9B).
- 381 SNX8 has higher expression in individuals with SARS-CoV-2 infections compared to uninfected

382 (Supplemental Figure 9C). Within myeloid lineage cells, SNX8 expression correlates with

MAVS expression, and OAS1 and OAS2 (two known regulators of the MAVS pathway specifically implicated in MIS-C pathogenesis(*41*)) expression (Supplemental Figure 9D). In

- specifically implicated in MIS-C pathogenesis(41)) expression (Supplemental Figure 9D).
- contrast to MAVS, SNX8 expression is inversely correlated to severity of SARS-CoV-2
- infection, with highest expression in asymptomatic individuals. This follows a similar pattern to

OAS1 and OAS2. However, unlike OAS1, OAS2, and MAVS, SNX8 is preferentially expressed

in SARS-CoV-2 infections relative to influenza virus infection (Supplemental Figure 9E).

389

Discussion 390

391 The SARS-CoV-2 pandemic largely spared children from severe disease. One rare but notable

- exception is MIS-C, an enigmatic and life-threatening syndrome. Children with MIS-C have 392
- 393 increased circulating inflammatory markers, dysregulated innate and adaptive immunity, and
- evidence of autoimmunity (17-23, 37, 58). Previous studies have surfaced numerous 394
- associations, but have failed to identify a direct mechanistic link between SARS-CoV-2 and 395
- MIS-C. Among those previously reported associated autoantibodies (20-22, 44), only 396
- autoantibodies targeting UBE3A and IL1RA were significantly enriched in this study, though 397
- anti-UBE3A antibodies were found in some controls and an association with anti-IL1RA 398
- antibodies were confounded by IVIG treatment. 399
- 400
- In this study, 199 MIS-C patient samples and 45 pediatric at-risk controls were analyzed using a 401
- customized human and SARS-CoV-2 proteome PhIP-seq library. In the human library, the 402 results reveal an autoreactive signature that distinguishes cases from controls, driven by 403
- enrichment of peptides deriving from three proteins, including SNX8, which is expressed by
- 404
- immune cells across multiple tissues. For SARS-CoV-2, differential enrichment between cases 405
- and controls was dominated by peptides derived from the N protein. Fine epitope mapping of 406
- both SNX8 and N protein identified a sequence that is highly similar, represented by the regular 407
- expression [ML]Q[ML]PQG. Furthermore, CD8+ T-cells were found to be cross-reactive for this 408 same epitope in MIS-C cases, but not controls. These cross-reactive cells may contribute to 409
- immune dysregulation through the inappropriate engagement of immune cell lineages expressing 410
- SNX8. Intriguingly, we found evidence for sharing of the [ML]Q[ML]PQG epitope between 411
- both B-cells and T-cells in our analysis and further study will be needed to understand this 412
- apparent convergence. Importantly, there is broad evidence that in many autoimmune diseases 413
- autoantibodies can target intracellular antigens, but pathology is thought to be driven by an 414
- 415 autoreactive T-cell response(31, 52).
- 416

These findings may help to clarify and connect several important known aspects of MIS-C 417 pathophysiology. Specifically, these results draw parallels to other diseases in which exposure to 418

- a new antigen leads to autoimmunity, such as paraneoplastic autoimmune disease or cross-419
- reactive viral epitopes between EBV and host proteins in multiple sclerosis(24–26, 31). An 420
- expansion of TRVB11-2 T-cells in MIS-C has been shown(23, 36–39), and while a superantigen 421
- has been postulated, it has yet to be identified. Recent studies have shown that tissue resident T-422
- cells exhibit site-specific expansions(59), and that MIS-C patients have a distinct increase in 423
- activated circulating T-cells with a tissue-resident phenotype (41), leading to speculation that 424
- these T-cells may be driving the TRVB11-2 expansion. Although SNX8 is a relatively 425
- understudied protein, it has been linked to the function and activity of MAVS(43). Importantly, 426
- dysregulation of the MAVS antiviral pathway, by inborn errors of immunity, has been shown to 427
- underly certain cases of MIS-C(41). The most straightforward connection linking MIS-C to 428
- SNX8 may be through an inappropriate autoimmune response against tissues with significant 429
- MAVS pathway expression, but further investigation will be needed to test this potential link. 430 431
- In addition to helping contextualize previous findings, these results are the first to directly link 432
- the initial SARS-CoV-2 infection and the subsequent development of MIS-C. We propose that 433
- 434 MIS-C may be the results of multiple uncommon events converging. The initial insult is likely
- the formation of a combined B-cell and T-cell response that preferentially targets a particular 435

- 436 motif within the N protein of SARS-CoV-2. A subset of individuals may then develop a cross-
- 437 reactive B-cell and T-cell response to the self-protein SNX8. Interestingly, this cross-reactive
- 438 motif has strong binding characteristics for the MIS-C associated HLA-A*02(*37*), further
- indicating that this may be an important risk factor in the development of MIS-C.
- 440

441 These results describe a subset of MIS-C (at least 17% positive for antibodies against SNX8),

- indicating that other mechanisms likely exist. Antibodies against ERFL are present in many
- children with MIS-C who do not have autoreactivity to SNX8, and ERFL has a highly similar
- tissue RNA expression profile to SNX8 (2nd most similar among all known proteins; Human
- 445 Protein Atlas; Proteinatlas.org). If autoreactive T-cells to ERFL indeed also exist, they would be
- 446 predicted to engage a nearly identical set of cells and tissues. It is important to also consider that
 447 MIS-C prevalence has rapidly decreased as an increasing number of children have developed
- immunity through vaccination and natural SARS-CoV-2 infection. We speculate that perhaps
- this could be related to the strong deviation of the anti-SARS CoV-2 immune response away
- 450 from the critical region of the N-protein that we have identified, to other major epitopes such as
- 451 those in the Spike protein through vaccination and past infection. Alternatively, ongoing
- 452 evolution of SARS-CoV-2 may include mutations in the N protein that could affect subsequent
- 453 antigen processing and presentation.
- 454

455 MIS-C is complex and more work is required to fully unravel the etiology. Why the differential

- adaptive immune response outlined above occurs in children with MIS-C and not others remains
- somewhat unclear. However, the results of this study, and specifically the development of
- combined cross-reactive B-cells and T-cells, bear similarity to other notable examples of
- 459 molecular mimicry. Future work is needed to examine the mechanisms by which a cross-reactive
- epitope forces a break in tolerance, which may point toward better diagnostics and therapeutic
- interventions for many diseases with similar underlying mechanisms.

462 Methods

463 Patients

Patients were recruited through the prospectively enrolling multicenter Overcoming COVID-19 464 and Taking on COVID-19 Together study in the United States. The study was approved by the 465 central Boston Children's Hospital Institutional Review Board (IRB) and reviewed by IRBs of 466 participating sites with CDC IRB reliance. A total of 292 patients were enrolled into 1 of the 467 following independent cohorts between June 1, 2020 and September 9, 2021: 223 patients 468 hospitalized with MIS-C (199 in the primary discovery cohort, 24 in a separate subsequent 469 validation cohort), 29 patients hospitalized for COVID-19 in either an intensive care or step-470 down unit (referred to as severe acute COVID-19 in this study), and 45 outpatients (referred to as 471 "at-risk controls" in this study) post-SARS-CoV-2 infections associated with mild or no 472 symptoms. The demographic and clinical data are summarized in Table I, Supplemental Table 1, 473 and Supplemental Table 2. The 2020 US Centers for Disease Control and Prevention case 474 475 definition was used to define MIS-C(60). All patients with MIS-C had positive SARS-CoV-2 serology results and/or positive SARS-CoV-2 test results by reverse transcriptase quantitative 476 PCR. All patients with severe COVID-19 or outpatient SARS-CoV-2 infections had a positive 477 antigen test or nucleic acid amplification test SARS-CoV-2. For outpatients, samples were 478

- 479 collected from 36 to 190 days after the positive test (median, 70 days after positive test; 480 interguartile range 56.81 days). For use as controls in the SAPS CoV 2 specific PhIP Set
- 480 interquartile range, 56-81 days). For use as controls in the SARS-CoV-2 specific PhIP-Seq,

- 481 plasma from 48 healthy, pre-COVID-19 controls were obtained as deidentified samples from the
- 482 New York Blood Center. These samples were part of retention tubes collected at the time of
- blood donations from volunteer donors who provided informed consent for their samples to be
- used for research.
- 485

486 DNA oligomers for split luciferase binding assays (SLBAs)

- 487 DNA coding for the desired peptides for use in split luciferase binding assays were inserted into
- 488 split luciferase constructs containing a terminal HiBiT tag and synthesized (Twist Biosciences)
- as DNA oligomers and verified by Twist Biosciences prior to shipment. Constructs were
- 490 amplified by PCR using the 5'- AAGCAGAGCTCGTTTAGTGAACCGTCAGA-3' and 5'-
- 491 GGCCGGCCGTTTAAACGCTGATCTT-3' primer pair.
- 492 For SNX8, the oligomers coded for the following sequences:

- 494

495 DNA plasmids for radioligand binding assays (RLBAs)

496 For radioligand binding assays, DNA expression plasmids under control of a T7 promoter and

under a T7 promoter was inserted into the pTwist Kan High Copy Vector (Twist Bioscience).

⁴⁹⁷ with a terminal Myc-DDK tag for the desired protein were utilized. For ERFL, a custom plasmid

⁴⁹⁸ was ordered from Twist Bioscience in which a Myc-DDK-tagged full length ERFL sequence

500 Twist Bioscience verified a sequence perfect clone by next generation sequencing prior to

- shipment. Upon receipt, the plasmid was sequence verified by Primordium Labs. For SNX8, a
- 502 plasmid containing Myc-DDK-tagged full length human SNX8 under a T7 promoter was ordered
- from Origene (RC205847) and was sequence verified by Primordium Labs upon receipt. For
- 504 KDELR1, a plasmid containing Myc-DDK-tagged full length human KDELR1 under a T7
- 505 promoter was ordered from Origene (RC205880), and was sequence verified by Primordium
- Labs upon receipt. For IL1RN, a plasmid containing Myc-DDK-tagged full length human IL1RN
- under a T7 promoter was ordered from Origene (RC218518), and was sequence verified byPrimordium Labs upon receipt.
- 509

510 Polypeptide pools for activation induced marker (AIM) assays

- 511 To obtain polypeptides tiling full length SNX8 protein, 15-mer polypeptide fragments with 11
- amino acid overlaps were ordered from JPT Peptide Technologies and synthesized. Together a
- pool of 130 of these polypeptides (referred to as "SNX8 Pool") spanned all known translated
- 514 SNX8 (the full length 465 amino acid SNX8 protein, as well as a unique region of SNX8
- 515 Isoform 3). A separate pool was designed to cover primarily the region of SNX8 with similarity
- to the SARS-CoV-2 nucleocapsid protein in high resolution (referred to as "high resolution
- epitope pool"). This pool contained 20 10-mers with 9 amino acid overlaps tiling amino acids 44
- through 72 (IVQQVPAPSRMQMPQGNPLLLSHTLQELL) of full length SNX8 protein. The
- sequence of each of these 150 polypeptides was verified by mass spectrometry and purity was
- 520 calculated by high-performance liquid chromatography (HPLC).
- 521

522 Peptides for tetramer assays

- 523 For use in loading tetramers, two peptides were ordered from Genemed Synthesis, Inc., as 9-
- 524 mers. One sequence, LQLPQGITL, corresponds to the region of the SARS-CoV-2 nucleocapsid
- 525 protein with similarity to human SNX8. This sequence was verified by mass spectrometry and
- 526 purity was calculated as 96.61% by HPLC. The other sequence, MQMPQGNPL, corresponds to
- 527 the region of human SNX8 protein with similarity to the SARS-CoV-2 nucleocapsid protein.
- 528 This sequence was verified by mass spectrometry and purity was calculated as 95.83% by HPLC.
- 529

530 Human proteome PhIP-Seq

- 531 Human Proteome PhIP-Seq was performed following our previously published vacuum-based
- 532 PhIP-Seq protocol (45) (https://www.protocols.io/view/scaled-high-throughput-vacuum-phip-
- 533 <u>protocol-ewov1459kvr2/v1</u>).
- 534
- 535 Our human peptidome library consists of a custom-designed phage library of 731,724 unique T7
- bacteriophage each presenting a different 49 amino-acid peptide on its surface. Collectively these
 peptides tile the entire human proteome including all known isoforms (as of 2016) with 25
- amino-acid overlaps. 1 milliliter of phage library was incubated with 1 microliter of human
- serum overnight at 4C and immunoprecipitated with 25 microliters of 1:1 mixed protein A and
- 540 protein G magnetic beads (Thermo Fisher, Waltham, MA, #10008D and #10009D). These beads
- 541 were than washed, and the remaining phage-antibody complexes were eluted in 1 milliliter of
- 542 E.Coli (BLT5403, EMD Millipore, Burlington, MA) at 0.5-0.7 OD and amplified by growing in
- 543 37C incubator. This new phage library was then re-incubated with the same individual's serum
- and the previously described protocol repeated. DNA was then extracted from the final phage-
- 545 library, barcoded, and PCR-amplified and Illumina adaptors added. Next-Generation Sequencing

was then performed using an Illumina sequencer (Illumina, San Diego, CA) to a read depth ofapproximately 1 million per sample.

548

549 Human proteome PhIP-Seq analysis

All human peptidome analysis (except when specifically stated otherwise) was performed at the gene-level, in which all reads for all peptides mapping to the same gene were summed, and 0.5

reads were added to each gene to allow inclusion of genes with zero reads in mathematical

- analyses. Within each individual sample, reads were normalized by converting to the percentage
- of total reads. To normalize each sample against background non-specific binding, a fold-change
- (FC) over mock-IP was calculated by dividing the sample read percentage for each gene by the
- 556 mean read-percentage of the same gene for the AG bead only controls. This FC signal was then
- used for side-by-side comparison between samples and cohorts. FC values were also used to
- calculate z-scores for each MIS-C patients relative to controls and for each control sample by
- using all remaining controls. These z-scores were used for the logistic-regression feature
- weighting. In instances of peptide-level analysis, raw reads were normalized by calculating the
- number of reads per 100,000 reads.
- 562

563 SARS-CoV-2 proteome PhIP-Seq

- 564 SARS-CoV-2 Proteome PhIP-Seq was performed as previously described(51). Briefly, 38 amino
- acids fragments tiling all open reading frames from SARS-CoV-2, SARS-CoV-1, and 7 other
- 566 CoVs were expressed on T7 bacteriophage with 19 amino acid overlaps. 1 milliliter of phage
- library was incubated with 1 microliter of human serum overnight at 4C and immunoprecipitated
 with 25 microliters of 1:1 mixed protein A and protein G magnetic beads (Thermo Fisher,
- Waltham, MA, #10008D and #10009D). Beads were washed 5 times on a magenetic plate using
- a P1000 multichannel pipette. The remaining phage-antibody complexes were eluted in 1
- milliliter of E.Coli (BLT5403, EMD Millipore, Burlington, MA) at 0.5-0.7 OD and amplified by
- growing in 37C incubator. This new phage library was then re-incubated with the same
- 573 individual's serum and the previously described protocol repeated for a total of 3 rounds of
- 574 immunoprecipitations. DNA was then extracted from the final phage-library, barcoded, and
- 575 PCR-amplified and Illumina adaptors added. Next-Generation Sequencing was then performed
- using an Illumina sequencer (Illumina, San Diego, CA) to a read depth of approximately 1
 million per sample.
- 578

579 Coronavirus proteome PhIP-Seq analysis

- To account for differing read depths between samples, the total number of reads for each peptide fragment was converted to the number of reads per 100k (RPK). To calculate normalized
- enrichment relative to pre-COVID controls (FC > Pre-COVID), the RPK for each peptide
- fragment within each sample was divided by the mean RPK of each peptide fragment among all
- pre-COVID controls. These FC > Pre-COVID values were used for all subsequent analyses as
- 585 described in the text and figures.
- 586

587 Radioligand binding assay (RLBA)

- 588 Radioligand binding assays were performed as previously described(45, 46).Briefly, DNA
- 589 plasmids containing full-length cDNA under the control of a T7 promoter for each of the
- validated antigens (see RLBA plasmids above) were verified by Primordium Labs sequencing.
- 591 The respective DNA templates were used in the T7 TNT in vitro transcription/translation kit

- (Promega, Madison, WI; #L1170) using [35S]-methionine (PerkinElmer, Waltham, MA;
- #NEG709A). Respective protein was column-purified on Nap-5 columns (GE healthcare,
- 594 Chicago, IL; #17-0853-01), and equal amounts of protein (approximately 35,000 counts per
- 595 minute (cpm)) were incubated overnight at 4 degrees C with 2.5 ul of serum or 1 ul anti-Myc
- positive control antibody (Cell Signaling Technology, #2272 S). Immunoprecipitation was then
- 597 performed on 25 microliters of Sephadex protein A/G beads (Sigma Aldrich, St. Louis, MO;
- ⁵⁹⁸ #GE17-5280-02 and #GE17-0618-05, 4:1 ratio) in 96-well polyvinylidene difluoride filtration
- plates (Corning, Corning, NY; #EK-680860). After thoroughly washing, the counts per minute
 (cpm) of immunoprecipitated protein was quantified using a 96-well Microbeta Trilux liquid
- (cpm) of immunoprecipitated protein was quantified using a 96-well Microbeta Trilux liquidscintillation plate reader (Perkin Elmer).
- 602

603 Split luciferase binding assay (SLBA)

SLBA was performed as described in Rackaityte et. al(61). A detailed SLBA protocol is available on protocols is at: dx doi org/10.17504/protocols is 4r3127b0pg1x/y1

- available on protocols.io at: dx.doi.org/10.17504/protocols.io.4r3l27b9pg1y/v1.
- 606

Briefly, the DNA oligomers listed above (SLBA DNA oligomers) were amplified by PCR using

- the primer pairs listed above (SLBA DNA oligomers). Unpurified PCR product was used as
- input in the T7 TNT in vitro transcription/translation kit (Promega, Madison, WI; #L1170) and
- Nano-Glo HiBit Lytic Detection System (Promega Cat No. N3040) was used to measure relative
- 611 luciferase units (RLU) of translated peptides in a luminometer. Equal amounts of protein (in the
- range of 2e6 to 2e7 RLU) were incubated overnight with 2.5 ul patient sera or 1ul anti-HiBit
- positive control antibody (Promega, Madison, WI; #CS2006A01)at 4 C. Immunoprecipitation
- was then performed on 25 microliters of Sephadex protein A/G beads (Sigma Aldrich, St. Louis,
- 615 MO; #GE17-5280-02 and #GE17-0618-05, 1:1 ratio) in 96-well polyvinylidene difluoride
- 616 filtration plates (Corning, Corning, NY; #EK-680860). After thoroughly washing, luminescence
- was measured using Nano-Glo HiBit Lytic Detection System (Promega Cat No. N3040) in a
 luminometer.
- 619

620 Activation induced marker (AIM) assay

Peripheral blood mononuclear cells (PBMCs) were obtained from 10 patients with MIS-C and 10 controls for use in the AIM assay. PBMCs were thawed, washed, resuspended in serum-free

RPMI medium, and plated at a concentration of $1e10^6$ cell/well in a 96-well round-bottom plate.

- For each individual, PBMCs were stimulated for 24-hours with either the SNX8 pool (see above)
- at a final concentration of 1 ug/mL/peptide in 0.2% DMSO, or a vehicle control containing 0.2%
- DMSO only. For 4 of the controls and 2 of the MIS-C patients, there were sufficient PBMCs for
- an additional stimulation condition using the SNX8 high resolution epitope pool (see above) also
- at a concentration of 1 ug/mL/peptide in 0.2% DMSO for 24-hours. Following the stimulation,
- cells were washed with FACS buffer (Dulbecco's PBS without calcium or magnesium, 0.1%
- sodium azide, 2 mM EDTA, 1% FBS) and stained with the following antibody panel for 20
- 631 minutes at 4 degrees and then flow cytometry analysis was immediately performed:
- 632

Antibody Target	Clone	Fluorophore	Vendor	Catalog #
CD3	OKT3	Alexa 647	BioLegend	317312
CD4	OKT4	Alexa 488	BioLegend	317420
CD8	SK1	Alexa 700	BioLegend	344724
OX-40 (CD134)	ACT35	PE-Dazzle 594	BioLegend	350020

CD69	FN-50	PE	BioLegend	310906
CD137 (4-1BB)	4B4-1	BV421	BioLegend	309820
CD14	HCD14	PerCP-Cy5.5	BioLegend	325622
CD16	B73.1	PerCP-Cy5.5	BioLegend	360712
CD19	HIB19	PerCP-Cy5.5	BioLegend	302230
Live/dead dye		eFluor 506	Invitrogen	65-0866-14

633

The AIM analysis was performed using FlowJo software using the gating strategy shown in 634

Supplemental Figure 10A. All gates were fixed within each condition of each sample. Activated 635

CD4 T-cells were defined as those which were co-positive for OX40 and CD137. Activated CD8 636

T-cells were defined as those which were co-positive for CD69 and CD137. Gating thresholds 637

for activation were defined by the outer limits of signal in the vehicle controls allowing for up to 638

2 outlier cells. Frequencies were calculated as a percentage of total CD3 positive cells (T-cells). 639

Two MIS-C samples had insufficient total events captured by flow cytometry (total of 5,099 and 640

4,919 events, respectively) and were therefore removed from analysis. 641

642

643 Tetramer Assav

PBMCs from 2 MIS-C patients with HLA-A*02.01 (1 identified by PAXGene genotyping, 1 by 644 serotyping) and 1 MIS-C patient with HLA-B*35.01 (identified by PAXGene genotyping), and 3 645 at-risk controls with HLA-A*02.01 (identified by serotyping) were thawed, washed, and put into 646 culture with media containing recombinant human IL-2 at 10 ng/mL in 96-well plates. Peptide 647 fragments (details above) LQLPQGITL and MQMPQGNPL were then added to PBMCs to a 648 final concentration of 10 ug/mL/peptide and incubated (37C, 5% CO2) for 7 days. 649

650

Following the 7 days of incubation, a total of 8 pMHCI tetramers were generated from UV-651

652 photolabile biotinylated monomers, 4 each from HLA-A*02:01 and HLA-B*35:01 (NIH

Tetramer Core). Peptides were loaded via UV peptide exchange. Tetramerization was carried out 653

using streptavidin conjugated to fluorophores PE and APC or BV421 followed by quenching 654

with 500uM D-biotin similar to our previously published methods(62, 63). Tetramers were then 655 pooled together as shown below:

656

657 658

HLA-A '02:01 F001			
Protein	Epitope	MHC I restriction	Fluorophore
SARS-CoV-2 NP	LQLPQGITL	A*02:01	PE
SARS-CoV-2 NP	LQLPQGITL	A*02:01	APC
SNX8	MQMPQGNPL	A*02:01	PE
SNX8	MQMPQGNPL	A*02:01	BV421

659

660 661

HLA-B*35:01 Pool				
Protein	Epitope	MHC I restriction	Fluorophore	
SARS-CoV-2 NP	LQLPQGITL	B*35:01	PE	
SARS-CoV-2 NP	LQLPQGITL	B*35:01	APC	
SNX8	MQMPQGNPL	B*35:01	PE	
SNX8	MQMPQGNPL	B*35:01	BV421	

All PBMCs were then treated with 100 nM Dasatinib (StemCell) for 30 min at 37 °C followed

by staining (no wash step) with the respective tetramer pool corresponding to their HLA

restriction (final concentration, 2 to $3 \mu g/ml$) for 30 min at room temperature. Cells were then

stained with the following cell surface markers for 20 minutes, followed by immediate analysison a flow cytometer:

667 668

Antibody Target	Clone	Fluorophore	Vendor	Catalog #
CD8	SK1	Alexa 700	BioLegend	357404
CD4	RPA-T4	PerCP-Cy5.5	BioLegend	300530
CD14	HCD14	PerCP-Cy5.5	BioLegend	325622
CD16	B73.1	PerCP-Cy5.5	BioLegend	360712
CD19	HIB19	PerCP-Cy5.5	BioLegend	302230
Streptavidin		PE	Invitrogen	S866
Streptavidin		APC	Invitrogen	S868
Streptavidin		BV421	BioLegend	405225
Live/dead dye		eFluor 506	Invitrogen	65-0866-14

669

The gating strategy is outlined in Supplemental Figure 10B. A stringent tetramer gating strategy

was used to identify cross-reactive T-cells, whereby CD8+ T-cells were required to be triple-

positive for PE, APC, and BV421 labels (i.e. a single CD8 T-cell bound to PE conjugated

673 LQLPQGITL and/or PE conjugated MQMPQGNPL in addition to APC-conjugated

674 LQLPQGITL and BV421 conjugated MQMPQGNPL).

675

676 Serotyping was performed using an anti-HLA-A2 antibody (FITC anti-human HLA-A2

Antibody, Clone BB7.2, BioLegend, Cat#343303), and pertinent results are shown inSupplemental Figure 10C.

679

680 Single Cell RNA Sequencing Analysis

To assess the cell-type specificity in a relevant disease context, we analyzed SNX8 expression

from a single-cell sequencing of PBMC samples from patients with severe, mild, or

asymptomatic COVID-19 infection, Influenza infection and healthy controls(57). Gene

expression data from 59,572 pre-filtered cells was downloaded from the GEO database under

accession <u>GSE149689</u> for analysis and downstream processing with scanpy(64). Cells with (i)

less than 1000 total counts, (ii) less than 800 expressed genes and (iii) more than 3000 expressed

genes were filtered out as further quality control, leaving 42,904 cells for downstream analysis.

Gene expression data were normalized to have 10,000 counts per cell and were $\log_1 P$

transformed. Highly variable genes were calculated using the scanpy function

highly_variable_genes using Seurat flavor with the default parameters (min_mean = 0.0125,

 $max_mean = 3$, and $min_disp = 0.5$)(65). Only highly variable genes were used for further

analysis. The total number of counts per cell was regressed out, and the gene expression matrix

was scaled using the scanpy function scale with $\max_{value} = 10$. Dimensionality reduction was

694 performed using principal components analysis with 50 principal components. Batch balanced

695 kNN (k-nearest neighbors), implemented with scanpy's function bbknn, was used to compute

each cell's top neighbors and normalize batch effects(66). The batch-corrected cells were

clustered using the Leiden algorithm and projected into two dimensions with uniform manifoldapproximation and projection (UMAP) for visualization. Initial cluster identity was determined

by finding marker genes with differential expression analysis preformed using a *t* test on $\log_1 P$ transformed raw counts with the scanpy function rank genes groups(67, 68).

701

702 Statistical methods

All statistical analysis was performed in Python using the Scipy Stats package. For comparisons

- of distributions of PhIP-Seq enrichment between two groups, a non-parametric Kolmogorov-
- Smirnov test was utilized. For logistic regression feature weighting, the Scikit-learn package(69)
- was used, and logistic regression classifiers were applied to z-scored PhIP-Seq values from
- individuals with MIS-C versus at-risk controls. A liblinear solver was used with L1
- regularization, and the model was evaluated using a five-fold cross-validation (4 of the 5 for training, 1 of the 5 for testing). For RLBAs and SLBAs, first an antibody index was calculated
- as follows: (sample value mean blank value) / (positive control antibody values mean blank
- values). For the alanine mutagenesis scans, blank values of each construct were combined, and a
- single mean was calculated. A normalization function was then applied to the experimental
- samples only (excluding antibody only controls) to create a normalized antibody index ranging
- from 0 to 1. Comparisons between two groups of samples were performed using a Mann-
- 715 Whitney U test. An antibody was considered to be "positive" when the normalized antibody
- index in a sample was greater than 3 standard deviations above the mean of controls. When

comparing two groups of normally distributed data, a T-test was performed. P-values: ns > 0.05, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001, **** < 0.0001.

719

720 Supplemental Tables

721

722 Supplemental Table 1: Phenotypic data for MIS-C patients.

723

Organ System Involvement (number reporting)	Phenotype Present	Percent
Respiratory		
Oxygen requirement (198)	139	70.2
Bronchospasm (161)	2	1.2
Acute Respiratory Distress Syndrome (ARDS) (198)	24	12.1
Cardiac		
Vasoactive support (198)	124	62.6
Myocarditis (199)	115	57.8
Elevated Troponin (197)	128	65
Neurologic		
Any neurologic symptoms (197)	22	11.2
Encephalitis (197)	2	1
Gastrointestinal (196)	66	33.7
Hematologic (197)	22	11.2
Rheumatologic		
Arthritis (195)	9	4.6
Myositis (194)	27	12.9
Mucocutaneous		

Conjunctivitis (197)	105	53.3
Oral Mucosal Changes (198)	76	38.4
Rash (197)	106	53.8

724

725 **Table Definitions:**

Oxygen requirement; receipt of any oxygen support at any time during hospitalization.

727 Bronchospasm; severe bronchospasm requiring continuous bronchodilators. Acute Respiratory

- 728 Distress Syndrome (ARDS); onset of hypoxemia was acute (during this illness), chest imaging
- findings of new infiltrates (unilateral or bilateral), respiratory failure not fully explained by cardiac failure or fluid overload, PaO2/FiO2 ratio < 300 or SpO2/FiO2 < 264 (if SpO2 < 97), on
- $CPAP > 5 \text{ cm H2O or BiPAP or Invasive Mechanical Ventilation. Vasoactive support; receipt of CPAP > 5 cm H2O or BiPAP or Invasive Mechanical Ventilation. Vasoactive support; receipt of$
- vasoactive infusions (at any time during hospitalization) including: Dopamine, Dobutamine,
- Epinephrine, Norepinephrine, Phenylephrine, Milrinone, Vasopressin (for hypotension, not
- diabetes insipidus). Myocarditis; myocarditis diagnosed during hospital stay and adjudicated by
- outside panel of cardiologists. Elevated troponin; based on site-specific cutoff. Any neurologic
- symptoms; suspected central nervous system infection, stroke or intracranial hemorrhage (at
- 737 presentation or during hospitalization), seizure (at presentation or during hospitalization), coma
- or unresponsive, receipt of neurodiagnostic imaging (CT, MRI, or LP), encephalitis, decreased

hearing, decreased vision, iritis or uveitis. Gastrointestinal; appendicitis, diarrhea (at presentation

- or during hospitalization), abdominal pain (at presentation or during hospitalization), gallbladder
 hydrops or edema, pancreatitis, hepatitis, nausea/loss of appetite at presentation, vomiting at
- presentation. Hematologic: anemia with hemoglobin <9 g/dL, minimum white blood cells <4 x

 10^3 cells/µL, minimum platelets <150 x 10^3 cells/µL, deep vein thrombosis, pulmonary

- embolism, hemolysis, bleeding, ischemia of an extremity. Oral Mucosal Changes; erythema of
- 745 lips or oropharynx, strawberry tongue, or drying or fissuring of the lips.
- 746

747 Supplemental Table 2: Clinical characteristics of validation cohorts

748

	Severe Acute COVID-19	MIS-C Validation
Number	29	24
Male sex (%)	14 (48.3)	16 (66.7)
Median age in years (median, IQR)	11.4 (11.4)	7.7 (8.6)
Race and ethnicity (%)		
White, non-Hispanic	14 (48.3)	3 (12.5)
Black, non-Hispanic	4 (13.8)	8 (33.3)
Hispanic or Latino	9 (31.0)	13 (54.2)
Other race, non-Hispanic	2 (6.9)	0 (0.0)
Underlying conditions (%)		
None	9 (31.0)	13 (54.2%)
Obesity*	8 (27.6)	7 (29.2)
Asthma	3 (10.3)	2 (8.3)
Cardiovascular	1 (3.4)	0 (0.0)
Immunocompromise	1 (3.4)	0 (0.0)

Autoimmune condition	0 (0.0)	0 (0.0)
Malignancy	1 (3.4)	0 (0.0)
Interventions (%)		
ICU admission	22 (75.9)	11 (45.8)
Shock requiring vasopressors	11 (37.9)	0 (0.0)
Mechanical ventilation	6 (20.7)	2 (8.3)

749

*Does not include n=4 acute COVID-19 patients and n=1 MIS-C patients under 2 years of age.

Acknowledgements. The following members of the Overcoming COVID-19 Network Study 750 Group Investigators (presented alphabetically by state) were all closely involved with the design, 751 implementation, and oversight of the Overcoming COVID-19 study as well as collecting patient 752 samples and data. Alabama: Children's of Alabama, Birmingham: Michele Kong, MD, Heather 753 754 Kelley, RN, BSN; Meghan Murdock, RN, BSN; Candice Colston. Arizona: Katri V. Typpo, MD. Arkansas: Arkansas Children's Hospital, Little Rock: Katherine Irby, MD; Ronald C. 755 Sanders Jr, MD, MS; Masson Yates; Chelsea Smith. California: UCSF Benioff Children's 756 Hospital Oakland, Oakland: Natalie Z. Cvijanovich, MD; UCSF Benioff Children's Hospital, 757 San Francisco: Matt S. Zinter, MD. Colorado: Aline B. Maddux, MD, MSCS, Emily Port, BA, 758 PMP; Rachel Mansour, BSN, RN, CPN; Sara Shankman, DNP, CPNC-AC, Natasha Baig, 759 MBBS, Frances Zorensky, BS.. Florida: Holtz Children's Hospital, Miami: Paula S. Espinal, 760 761 MD, MPH; Brandon Chatani, MD; Gwenn McLaughlin, MD, MSPH. Georgia: Children's Healthcare of Atlanta at Egleston, Atlanta: Keiko M. Tarquinio, MD; Kaitlin Jones, MSN, RN, 762 CCRP. Illinois: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago: Bria M. 763 Coates, MD. Indiana: Riley Children's Hospital, Indianapolis: Courtney M. Rowan, MD, 764 MScr. *Massachusetts:* Boston Children's Hospital, Boston: Adrienne G. Randolph, MD; 765 Margaret M. Newhams, MPH; Suden Kucukak, MD; Tanya Novak, PhD; Elizabeth R. 766 767 McNamara BSN, RN; Hye Kyung Moon, MA; Takuma Kobayashi BS; Jeni Melo, BS; Sergio R. Jackson, MS; Marah Kiana Echon Rosales, BS; Cameron Young, BS; Sabrina R. Chen, BS; 768 Janet Chou, MD; Rezende Da Costa Aguiar, PhD; Maria Gutierrez-Arcelus, PhD, Megan Elkins, 769 MHS. Taking On COVID-19 Together team: David Williams, MD; Lucinda Williams, DNP, 770 MSN, RN, PNP, NE-BC; Leah Cheng, MA; Yubo Zhang, BS; Danielle Crethers, BA; Debra 771 Morley, PhD; Sarah Steltz, MPH; Kelly Zakar, MSN, RN, PPCNP-BC; Myriam A. Armant, 772 773 PhD; Felicia Ciuculescu, MD; Michigan: University of Michigan C. S. Mott Children's Hospital, Ann Arbor: Heidi R. Flori, MD, FAAP; Mary K. Dahmer, PhD. Minnesota: Mayo Clinic, 774 Rochester: Emily R. Levy, MD, FAAP; Supriya Behl, MSc; Noelle M. Drapeau, BA. 775 776 *Mississippi:* Charlotte V. Hobbs, MD *Missouri:* Children's Mercy Hospital, Kansas City: 777 Jennifer E. Schuster, MD; Abigail Kietzman BS; Shannon Hill, BSN. Nebraska: Children's Hospital & Medical Center, Omaha: Melissa L. Cullimore, MD, PhD; Russell J. McCulloh, 778 779 MD. New Jersey: Cooperman Barnabas Medical Center, Livingston: Shira J. Gertz, MD. North Carolina: University of North Carolina, Chapel Hill: Stephanie P. Schwartz, MD; Tracie C. 780 Walker, MD. Ohio: Akron Children's Hospital, Akron: Ryan A. Nofziger, MD; Cincinnati 781 782 Children's Hospital, Cincinnati: Mary Allen Staat, MD, MPH; Chelsea C. Rohlfs, BS, MBA. Pennsylvania: Children's Hospital of Philadelphia, Philadelphia: Julie C. Fitzgerald, MD, 783 PhD, MSCE; Ryan Burnett, BS, Jenny Bush, RNC, BSN. South Carolina: MUSC Shawn Jenkins 784 785 Children's Hospital, Charleston: Elizabeth H. Mack, MD, MS; Nelson Reed, MD. Tennessee: Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville: Natasha B. 786

- 787 Halasa, MD, MPH. *Texas:* Texas Children's Hospital and Baylor College of Medicine, Houston:
- Laura L. Loftis, MD. *Utah:* Primary Children's Hospital and University of Utah, Salt Lake City:
 Hillary Crandall, MD, PhD; Kwabena Krow Ampofo, MD.
- 790 Members of the US Centers for Disease Control and Prevention COVID-19 Response Team on
- 791 the Overcoming COVID-19 Study were Laura D. Zambrano, PhD, MPH, Manish M. Patel, MD,
- MPH, and Angela P. Campbell, MD, MPH.
- The authors acknowledge the New York Blood Center for contributing pre-COVID-19 healthy donor blood samples which were used as controls for the SARS-CoV-2 library PhIP-Seq.
- The authors acknowledge the contributions of Weston Browne and Sam Pleasure, MD, PhD for
- their work investigating potential central nervous system specific autoimmunity in MIS-C; Tirtha
- Kharel, BS, for his help designing Python code used in the analysis; David Blauvelt, MD, for his
- ⁷⁹⁸ ideas regarding the application of advanced statistics to PhIP-Seq data analysis.
- Biorender (Biorender.com) was used to build graphics for Figure 1A and Figure 4C.
- **Disclaimer:** The findings and conclusions in this report are those of the authors and do not
- necessarily represent the views of the US Centers for Disease Control and Prevention.

802 **Contributions:**

- 803 Conceptualization: A.B, J.J.S.Jr., S.E.V., J.C., A.G.R., M.S.A., J.L.D. Methodology: A.B,
- 804 J.J.S.Jr., S.E.V., E.R., C.R.Z., A.F.K., J.V.R., J.C., A.G.R., M.S.A., J.L.D. Performed or
- contributed to experiments: A.B., J.J.S.Jr., S.E.V., A.M., C.Y.W., A.S., J.V.P., D.J.L.Y., H.K.,
- 806 C.M.B. Formal analysis: A.B., J.J.S.Jr., H.S.M., A.F.K. Patient sample and clinical data
- 807 acquisition: K.Z., T.N., L.D.Z., A.P.C., A.G.R.K.L.M., L.L.L, C.V.H, K.M.T, M.K, J.C.F, P.S.E,
- 808 T.C.W, S.P.S., H.C., K.I., M.A.S., C.M.R., J.E.S., N.B.H., S.J.G., E.H.M., A.B.M., N.Z.C.,
- 809 M.S.Z. Clinical data curation: T.N., A.G.R. Writing (original draft): A.B., H.M., J.L.D. Writing
- 810 (review and editing): A.B., J.C., T.N., H.M., L.D.Z., A.P.C, A.G.R., M.R.W., M.S.A., J.L.D.
- 811 Supervision: J.C., A.G.R., M.S.A., J.L.D.

812 Funding:

- This work was supported by the Pediatric Scientist Development Program and the Eunice
- Kennedy Shriver National Institute of Child Health and Human Development (K12-HD000850
- to A.B.), and the Chan Zuckerberg Biohub SF (J.L.D. and M.S.A.). Overcoming COVID-19
- 816 Study Network enrollment, patient data, and specimen collections supported by the CDC
- contracts 75D30120C07725, 75D30121C10297 and 75D30122C13330 from the Centers for
- Disease Control and Prevention to Boston Children's Hospital to A.G.R. and the National
- Institute of Allergy and Infectious Diseases (R01AI154470) to A.G.R. Patient clinical data and
- specimens also collected at Boston Children's Hospital for the Taking on COVID-19 Together
- 821 (TOCT) study supported in part by the Boston Children's Hospital Emerging Pathogens and

822 Epidemic Response Cluster of Clinical Research Excellence and the Institutional Centers for

823 Clinical and Translational Research to A.G.R. and K.L.M.

824 **Competing Interests:**

825

J.D.R. reports being a founder and paid consultant for Delve Bio, Inc., and a paid consultant for 826 the Public Health Company and Allen & Co. M.A.S. receives unrelated research funding from 827 the NIH, the CDC, Cepheid and Merck and unrelated Honoria from UpToDate, Inc. M.R.W. 828 receives unrelated research grant funding from Roche/Genentech and Novartis, and received 829 speaking honoraria from Genentech, Takeda, WebMD, and Novartis. J.C. reports consulting fees 830 from GLG group, payments from Elsevier for work as an Associate Editor, a patent pending for 831 832 methods and compositions for treating and preventing T cell-driven diseases, payments related to participation on a Data Safety Monitoring Board or Advisory Board for Enzyvant and is a 833 member of the Diagnostic Laboratory Immunology Committee of the Clinical Immunology 834 Society. M.S.Z. receives unrelated funding from NHLBI and consults for Sobi. N.B.H reports 835 836 unrelated previous grant support from Sanofi and Qudiel, and current grant support from Merck. C.V.H. reports being a speaker fo Biofire, and a reviewer for UpToDate, Inc, and Dynamed.com. 837 A.G.R. receives royalties as a section editor for Pediatric Critical Care Medicine UpToDate, Inc, 838

and also received Honoraria for MIS-C-related Grand Round Presentations. A.G.R. is also on the

medical advisor board of Families Fighting Flu and is Chair of the International Sepsis Forum

841 which is supported by industry and has received reagents from Illumina, Inc.

842 **Corresponding authors:**

843 Correspondence to Joseph L. DeRisi and Mark S. Anderson.

844 **References**

- 845
 846
 1. M. O'Driscoll, G. Ribeiro Dos Santos, L. Wang, D. A. T. Cummings, A. S. Azman, J. Paireau, A. Fontanet, S. Cauchemez, H. Salje, Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*. 590, 140–145
 848
 (2021).
- E. J. Williamson, A. J. Walker, K. Bhaskaran, S. Bacon, C. Bates, C. E. Morton, H. J. Curtis, A. Mehrkar, D.
 Evans, P. Inglesby, J. Cockburn, H. I. McDonald, B. MacKenna, L. Tomlinson, I. J. Douglas, C. T. Rentsch, R.
 Mathur, A. Y. S. Wong, R. Grieve, D. Harrison, H. Forbes, A. Schultze, R. Croker, J. Parry, F. Hester, S.
 Harper, R. Perera, S. J. W. Evans, L. Smeeth, B. Goldacre, Factors associated with COVID-19-related death
 using OpenSAFELY. *Nature*. 584, 430–436 (2020).
- 854 3. P. Brodin, Immune determinants of COVID-19 disease presentation and severity. *Nat. Med.* 27, 28–33 (2021).
- X. Lu, L. Zhang, H. Du, J. Zhang, Y. Y. Li, J. Qu, W. Zhang, Y. Wang, S. Bao, Y. Li, C. Wu, H. Liu, D. Liu, J.
 Shao, X. Peng, Y. Yang, Z. Liu, Y. Xiang, F. Zhang, R. M. Silva, K. E. Pinkerton, K. Shen, H. Xiao, S. Xu, G.
 W. K. Wong, Chinese Pediatric Novel Coronavirus Study Team, SARS-CoV-2 Infection in Children. *N. Engl. J. Med.* 382, 1663–1665 (2020).
- F. Götzinger, B. Santiago-García, A. Noguera-Julián, M. Lanaspa, L. Lancella, F. I. Calò Carducci, N.
 Gabrovska, S. Velizarova, P. Prunk, V. Osterman, U. Krivec, A. Lo Vecchio, D. Shingadia, A. Soriano Arandes, S. Melendo, M. Lanari, L. Pierantoni, N. Wagner, A. G. L'Huillier, U. Heininger, N. Ritz, S. Bandi,
 N. Krajcar, S. Roglić, M. Santos, C. Christiaens, M. Creuven, D. Buonsenso, S. B. Welch, M. Bogyi, F.

- 863 Brinkmann, M. Tebruegge, ptbnet COVID-19 Study Group, COVID-19 in children and adolescents in Europe: 864 a multinational, multicentre cohort study. *Lancet Child Adolesc Health.* **4**, 653–661 (2020).
- 865
 6. R. M. Viner, O. T. Mytton, C. Bonell, G. J. Melendez-Torres, J. Ward, L. Hudson, C. Waddington, J. Thomas,
 866
 867
 868
 868
 868
 868
 869
 869
 860
 860
 860
 860
 861
 862
 863
 864
 864
 865
 865
 866
 866
 866
 866
 867
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868
 868</li
- J. Chou, P. G. Thomas, A. G. Randolph, Immunology of SARS-CoV-2 infection in children. *Nat. Immunol.* 23, 177–185 (2022).
- L. S. Shekerdemian, N. R. Mahmood, K. K. Wolfe, B. J. Riggs, C. E. Ross, C. A. McKiernan, S. M.
 Heidemann, L. C. Kleinman, A. I. Sen, M. W. Hall, M. A. Priestley, J. K. McGuire, K. Boukas, M. P. Sharron,
 J. P. Burns, International COVID-19 PICU Collaborative, Characteristics and Outcomes of Children With
 Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units.
 JAMA Pediatr. 174, 868–873 (2020).
- E. Whittaker, A. Bamford, J. Kenny, M. Kaforou, C. E. Jones, P. Shah, P. Ramnarayan, A. Fraisse, O. Miller,
 P. Davies, F. Kucera, J. Brierley, M. McDougall, M. Carter, A. Tremoulet, C. Shimizu, J. Herberg, J. C. Burns,
 H. Lyall, M. Levin, PIMS-TS Study Group and EUCLIDS and PERFORM Consortia, Clinical Characteristics
 of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS CoV-2. JAMA. 324, 259–269 (2020).
- 881 10. L. R. Feldstein, M. W. Tenforde, K. G. Friedman, M. Newhams, E. B. Rose, H. Dapul, V. L. Soma, A. B. 882 Maddux, P. M. Mourani, C. Bowens, M. Maamari, M. W. Hall, B. J. Riggs, J. S. Giuliano Jr, A. R. Singh, S. 883 Li, M. Kong, J. E. Schuster, G. E. McLaughlin, S. P. Schwartz, T. C. Walker, L. L. Loftis, C. V. Hobbs, N. B. 884 Halasa, S. Doymaz, C. J. Babbitt, J. R. Hume, S. J. Gertz, K. Irby, K. N. Clouser, N. Z. Cvijanovich, T. T. 885 Bradford, L. S. Smith, S. M. Heidemann, S. P. Zackai, K. Wellnitz, R. A. Nofziger, S. M. Horwitz, R. W. 886 Carroll, C. M. Rowan, K. M. Tarquinio, E. H. Mack, J. C. Fitzgerald, B. M. Coates, A. M. Jackson, C. C. 887 Young, M. B. F. Son, M. M. Patel, J. W. Newburger, A. G. Randolph, Overcoming COVID-19 Investigators, Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in 888 Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 325, 1074–1087 (2021). 889
- I. J. Y. Abrams, M. E. Oster, S. E. Godfred-Cato, B. Bryant, S. D. Datta, A. P. Campbell, J. W. Leung, C. A.
 Tsang, T. J. Pierce, J. L. Kennedy, T. A. Hammett, E. D. Belay, Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. *Lancet Child Adolesc Health.* 5, 323–331 (2021).
- 894 12. covid-19-pediatric-multi-system-inflammatory-syndrome.pdf (available at https://www1.nyc.gov/assets/doh/downloads/pdf/han/alert/2020/covid-19-pediatric-multi-systeminflammatory-syndrome.pdf).
- 897 13. S. Riphagen, X. Gomez, C. Gonzalez-Martinez, N. Wilkinson, P. Theocharis, Hyperinflammatory shock in
 898 children during COVID-19 pandemic. *Lancet.* 395 (2020), pp. 1607–1608.
- R. M. Viner, E. Whittaker, Kawasaki-like disease: emerging complication during the COVID-19 pandemic.
 Lancet. 395 (2020), pp. 1741–1743.
- 15. L. Verdoni, A. Mazza, A. Gervasoni, L. Martelli, M. Ruggeri, M. Ciuffreda, E. Bonanomi, L. D'Antiga, An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet.* 395, 1771–1778 (2020).
- F. Sperotto, K. G. Friedman, M. B. F. Son, C. J. VanderPluym, J. W. Newburger, A. Dionne, Cardiac
 manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive
 review and proposed clinical approach. *Eur. J. Pediatr.* 180, 307–322 (2021).

- P07
 17. C. Diorio, S. E. Henrickson, L. A. Vella, K. O. McNerney, J. Chase, C. Burudpakdee, J. H. Lee, C. Jasen, F.
 P08
 P09
 P09
 P09
 P09
 P09
 P09
 P009
 P000
 P000</
- 18. L. A. Vella, J. R. Giles, A. E. Baxter, D. A. Oldridge, C. Diorio, L. Kuri-Cervantes, C. Alanio, M. B. Pampena,
 J. E. Wu, Z. Chen, Y. J. Huang, E. M. Anderson, S. Gouma, K. O. McNerney, J. Chase, C. Burudpakdee, J. H.
 Lee, S. A. Apostolidis, A. C. Huang, D. Mathew, O. Kuthuru, E. C. Goodwin, M. E. Weirick, M. J. Bolton, C.
- P. Arevalo, A. Ramos, C. J. Jasen, P. E. Conrey, S. Sayed, H. M. Giannini, K. D'Andrea, UPenn COVID
 Processing Unit, N. J. Meyer, E. M. Behrens, H. Bassiri, S. E. Hensley, S. E. Henrickson, D. T. Teachey, M. R.
 Betts, E. J. Wherry, Deep immune profiling of MIS-C demonstrates marked but transient immune activation
 compared to adult and pediatric COVID-19. *Sci Immunol.* 6 (2021), doi:10.1126/sciimmunol.abf7570.
- M. J. Carter, M. Fish, A. Jennings, K. J. Doores, P. Wellman, J. Seow, S. Acors, C. Graham, E. Timms, J.
 Kenny, S. Neil, M. H. Malim, S. M. Tibby, M. Shankar-Hari, Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nat. Med.* 26, 1701–1707 (2020).
- R. A. Porritt, A. Binek, L. Paschold, M. N. Rivas, A. McArdle, L. M. Yonker, G. Alter, H. K. Chandnani, M. Lopez, A. Fasano, J. E. Van Eyk, M. Binder, M. Arditi, The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. *J. Clin. Invest.* 131 (2021), doi:10.1172/JCI151520.
- 21. C. R. Consiglio, N. Cotugno, F. Sardh, C. Pou, D. Amodio, L. Rodriguez, Z. Tan, S. Zicari, A. Ruggiero, G. R.
 Pascucci, V. Santilli, T. Campbell, Y. Bryceson, D. Eriksson, J. Wang, A. Marchesi, T. Lakshmikanth, A.
 Campana, A. Villani, P. Rossi, CACTUS Study Team, N. Landegren, P. Palma, P. Brodin, The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. *Cell.* 183, 968-981.e7 (2020).
- 22. C. N. Gruber, R. S. Patel, R. Trachtman, L. Lepow, F. Amanat, F. Krammer, K. M. Wilson, K. Onel, D.
 23. Geanon, K. Tuballes, M. Patel, K. Mouskas, T. O'Donnell, E. Merritt, N. W. Simons, V. Barcessat, D. M. Del
 24. Valle, S. Udondem, G. Kang, S. Gangadharan, G. Ofori-Amanfo, U. Laserson, A. Rahman, S. Kim-Schulze, A.
 25. W. Charney, S. Gnjatic, B. D. Gelb, M. Merad, D. Bogunovic, Mapping Systemic Inflammation and Antibody
 26. Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). *Cell*. 183, 982-995.e14 (2020).
- 23. A. Ramaswamy, N. N. Brodsky, T. S. Sumida, M. Comi, H. Asashima, K. B. Hoehn, N. Li, Y. Liu, A. Shah, N.
 G. Ravindra, J. Bishai, A. Khan, W. Lau, B. Sellers, N. Bansal, P. Guerrerio, A. Unterman, V. Habet, A. J.
 Rice, J. Catanzaro, H. Chandnani, M. Lopez, N. Kaminski, C. S. Dela Cruz, J. S. Tsang, Z. Wang, X. Yan, S.
 H. Kleinstein, D. van Dijk, R. W. Pierce, D. A. Hafler, C. L. Lucas, Immune dysregulation and autoreactivity
 correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. *Immunity*. 54, 1083-1095.e7 (2021).
- Y. Lanz, R. C. Brewer, P. P. Ho, J.-S. Moon, K. M. Jude, D. Fernandez, R. A. Fernandes, A. M. Gomez, G.S. Nadj, C. M. Bartley, R. D. Schubert, I. A. Hawes, S. E. Vazquez, M. Iyer, J. B. Zuchero, B. Teegen, J. E.
 Dunn, C. B. Lock, L. B. Kipp, V. C. Cotham, B. M. Ueberheide, B. T. Aftab, M. S. Anderson, J. L. DeRisi, M.
 R. Wilson, R. J. M. Bashford-Rogers, M. Platten, K. C. Garcia, L. Steinman, W. H. Robinson, Clonally
 expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. *Nature*. 603, 321–327 (2022).
- 946
 95. O. G. Thomas, M. Bronge, K. Tengvall, B. Akpinar, O. B. Nilsson, E. Holmgren, T. Hessa, G. Gafvelin, M. Khademi, L. Alfredsson, R. Martin, A. O. Guerreiro-Cacais, H. Grönlund, T. Olsson, I. Kockum, Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis. *Sci Adv.* 9, eadg3032 (2023).
- 26. K. Tengvall, J. Huang, C. Hellström, P. Kammer, M. Biström, B. Ayoglu, I. Lima Bomfim, P. Stridh, J. Butt,
 N. Brenner, A. Michel, K. Lundberg, L. Padyukov, I. E. Lundberg, E. Svenungsson, I. Ernberg, S. Olafsson, A.
 T. Dilthey, J. Hillert, L. Alfredsson, P. Sundström, P. Nilsson, T. Waterboer, T. Olsson, I. Kockum, Molecular
 mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. *Proc. Natl. Acad. Sci. U. S. A.* 116, 16955–16960 (2019).

- N. E. Blachère, D. E. Orange, B. D. Santomasso, J. Doerner, P. K. Foo, M. Herre, J. Fak, S. Monette, E. C. Gantman, M. O. Frank, R. B. Darnell, T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. *Eur. J. Immunol.* 44, 3240–3251 (2014).
- R. B. Darnell, Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. *Proc. Natl. Acad. Sci. U. S. A.* 93, 4529–4536 (1996).
- B. O'Donovan, C. Mandel-Brehm, S. E. Vazquez, J. Liu, A. V. Parent, M. S. Anderson, T. Kassimatis, A.
 Zekeridou, S. L. Hauser, S. J. Pittock, E. Chow, M. R. Wilson, J. L. DeRisi, High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display. *Brain Commun.* 2, fcaa059 (2020).
- 30. R. B. Darnell, J. B. Posner, Paraneoplastic syndromes involving the nervous system. *N. Engl. J. Med.* 349, 1543–1554 (2003).
- W. K. Roberts, I. J. Deluca, A. Thomas, J. Fak, T. Williams, N. Buckley, A. G. Dousmanis, J. B. Posner, R. B. Darnell, Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. *J. Clin. Invest.* 119, 2042–2051 (2009).
- W. K. Roberts, R. B. Darnell, Neuroimmunology of the paraneoplastic neurological degenerations. *Curr. Opin. Immunol.* 16, 616–622 (2004).
- 33. C. Mandel-Brehm, D. Dubey, T. J. Kryzer, B. D. O'Donovan, B. Tran, S. E. Vazquez, H. A. Sample, K. C.
 Zorn, L. M. Khan, I. O. Bledsoe, A. McKeon, S. J. Pleasure, V. A. Lennon, J. L. DeRisi, M. R. Wilson, S. J.
 Pittock, Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. *N. Engl. J. Med.* 381, 47–54 (2019).
- 34. A. Venkatraman, P. Opal, Paraneoplastic cerebellar degeneration with anti-Yo antibodies a review. *Ann Clin Transl Neurol.* 3, 655–663 (2016).
- J. Pfeifer, B. Thurner, C. Kessel, N. Fadle, P. Kheiroddin, E. Regitz, M.-C. Hoffmann, I. A. Kos, K.-D. Preuss,
 Y. Fischer, K. Roemer, S. Lohse, K. Heyne, M.-C. Detemple, M. Fedlmeier, H. Juenger, H. Sauer, S. Meyer, T.
 Rohrer, H. Wittkowski, S. L. Becker, K. Masjosthusmann, R. Bals, S. Gerling, S. Smola, M. Bewarder, E. Birk,
 A. Keren, M. Böhm, A. Jakob, H. Abdul-Khaliq, J. Anton, M. Kabesch, R. M. Pino-Ramirez, D. Foell, L.
 Thurner, Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in
 children: a multicentre, retrospective, cohort study. *Lancet Rheumatol.* 4, e329–e337 (2022).
- 82 36. R. A. Porritt, L. Paschold, M. N. Rivas, M. H. Cheng, L. M. Yonker, H. Chandnani, M. Lopez, D. Simnica, C. Schultheiß, C. Santiskulvong, J. Van Eyk, J. K. McCormick, A. Fasano, I. Bahar, M. Binder, M. Arditi, HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. *J. Clin. Invest.* 131 (2021), doi:10.1172/JCI146614.
- 986 37. K. Sacco, R. Castagnoli, S. Vakkilainen, C. Liu, O. M. Delmonte, C. Oguz, I. M. Kaplan, S. Alehashemi, P. D. 987 Burbelo, F. Bhuyan, A. A. de Jesus, K. Dobbs, L. B. Rosen, A. Cheng, E. Shaw, M. S. Vakkilainen, F. Pala, J. 988 Lack, Y. Zhang, D. L. Fink, V. Oikonomou, A. L. Snow, C. L. Dalgard, J. Chen, B. A. Sellers, G. A. 989 Montealegre Sanchez, K. Barron, E. Rey-Jurado, C. Vial, M. C. Poli, A. Licari, D. Montagna, G. L. Marseglia, 990 F. Licciardi, U. Ramenghi, V. Discepolo, A. Lo Vecchio, A. Guarino, E. M. Eisenstein, L. Imberti, A. Sottini, 991 A. Biondi, S. Mató, D. Gerstbacher, M. Truong, M. A. Stack, M. Magliocco, M. Bosticardo, T. Kawai, J. J. 992 Danielson, T. Hulett, M. Askenazi, S. Hu, NIAID Immune Response to COVID Group, Chile MIS-C Group, 993 Pavia Pediatric COVID-19 Group, J. I. Cohen, H. C. Su, D. B. Kuhns, M. S. Lionakis, T. M. Snyder, S. M. 994 Holland, R. Goldbach-Mansky, J. S. Tsang, L. D. Notarangelo, Immunopathological signatures in multisystem 995 inflammatory syndrome in children and pediatric COVID-19. Nat. Med. 28, 1050-1062 (2022).
- M. Moreews, K. Le Gouge, S. Khaldi-Plassart, R. Pescarmona, A.-L. Mathieu, C. Malcus, S. Djebali, A.
 Bellomo, O. Dauwalder, M. Perret, M. Villard, E. Chopin, I. Rouvet, F. Vandenesh, C. Dupieux, R. Pouyau, S.
 Teyssedre, M. Guerder, T. Louazon, A. Moulin-Zinsch, M. Duperril, H. Patural, L. Giovannini-Chami, A.
 Portefaix, B. Kassai, F. Venet, G. Monneret, C. Lombard, H. Flodrops, J.-M. De Guillebon, F. Bajolle, V.
 Launay, P. Bastard, S.-Y. Zhang, V. Dubois, O. Thaunat, J.-C. Richard, M. Mezidi, O. Allatif, K. Saker, M.

1001	Dreux, L. Abel, JL. Casanova, J. Marvel, S. Trouillet-Assant, D. Klatzmann, T. Walzer, E. Mariotti-
1002	Ferrandiz, E. Javouhey, A. Belot, Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a
1003	hallmark of Multisystem Inflammatory Syndrome in Children. Sci Immunol. 6 (2021),
1004	doi:10.1126/sciimmunol.abh1516.

- 1005 39. L. Hoste, L. Roels, L. Naesens, V. Bosteels, S. Vanhee, S. Dupont, C. Bosteels, R. Browaeys, N. Vandamme,
 1006 K. Verstaen, J. Roels, K. F. A. Van Damme, B. Maes, E. De Leeuw, J. Declercq, H. Aegerter, L. Seys, U.
 1007 Smole, S. De Prijck, M. Vanheerswynghels, K. Claes, V. Debacker, G. Van Isterdael, L. Backers, K. B. M.
 1008 Claes, P. Bastard, E. Jouanguy, S.-Y. Zhang, G. Mets, J. Dehoorne, K. Vandekerckhove, P. Schelstraete, J.
 1009 Willems, MIS-C Clinicians, P. Stordeur, S. Janssens, R. Beyaert, Y. Saeys, J.-L. Casanova, B. N. Lambrecht,
 1010 F. Haerynck, S. J. Tavernier, TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and
 1011 CD16+ NK cells delineate MIS-C. J. Exp. Med. 219 (2022), doi:10.1084/jem.20211381.
- 40. K. Rybkina, J. N. Bell, M. C. Bradley, T. Wohlbold, M. Scafuro, W. Meng, R. C. Korenberg, J. Davis-Porada,
 B. R. Anderson, R. J. Weller, J. D. Milner, A. Moscona, M. Porotto, E. T. Luning Prak, K. Pethe, T. J.
 Connors, D. L. Farber, SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C
 compared to COVID-19. *J. Exp. Med.* 220 (2023), doi:10.1084/jem.20221518.
- 1016 41. D. Lee, J. Le Pen, A. Yatim, B. Dong, Y. Aquino, M. Ogishi, R. Pescarmona, E. Talouarn, D. Rinchai, P. 1017 Zhang, M. Perret, Z. Liu, I. Jordan, S. Elmas Bozdemir, G. I. Bayhan, C. Beaufils, L. Bizien, A. Bisiaux, W. 1018 Lei, M. Hasan, J. Chen, C. Gaughan, A. Asthana, V. Libri, J. M. Luna, F. Jaffré, H.-H. Hoffmann, E. 1019 Michailidis, M. Moreews, Y. Seeleuthner, K. Bilguvar, S. Mane, C. Flores, Y. Zhang, A. A. Arias, R. Bailey, 1020 A. Schlüter, B. Milisavljevic, B. Bigio, T. Le Voyer, M. Materna, A. Gervais, M. Moncada-Velez, F. Pala, T. 1021 Lazarov, R. Levy, A.-L. Neehus, J. Rosain, J. Peel, Y.-H. Chan, M.-P. Morin, R. M. Pino-Ramirez, S. Belkava, 1022 L. Lorenzo, J. Anton, S. Delafontaine, J. Toubiana, F. Bajolle, V. Fumadó, M. L. DeDiego, N. Fidouh, F. 1023 Rozenberg, J. Pérez-Tur, S. Chen, T. Evans, F. Geissmann, P. Lebon, S. R. Weiss, D. Bonnet, X. Duval, CoV-1024 Contact Cohort§, H. G. E. Covid, O. Pan-Hammarström, A. M. Planas, I. Meyts, F. Haerynck, A. Pujol, V. 1025 Sancho-Shimizu, C. Dalgard, J. Bustamante, A. Puel, S. Boisson-Dupuis, B. Boisson, T. Maniatis, Q. Zhang, P. 1026 Bastard, L. Notarangelo, V. Béziat, R. Perez de Diego, C. Rodriguez-Gallego, H. C. Su, R. P. Lifton, E. Jouanguy, A. Cobat, L. Alsina, S. Keles, E. Haddad, L. Abel, A. Belot, L. Quintana-Murci, C. M. Rice, R. H. 1027 1028 Silverman, S.-Y. Zhang, J.-L. Casanova, Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem 1029 inflammatory syndrome in children. Science, eabo3627 (2022).
- 42. W. Guo, J. Wei, X. Zhong, R. Zang, H. Lian, M.-M. Hu, S. Li, H.-B. Shu, Q. Yang, SNX8 modulates the
 innate immune response to RNA viruses by regulating the aggregation of VISA. *Cell. Mol. Immunol.* 17, 1126–1135 (2020).
- 43. H. B. Larman, Z. Zhao, U. Laserson, M. Z. Li, A. Ciccia, M. A. M. Gakidis, G. M. Church, S. Kesari, E. M.
 Leproust, N. L. Solimini, S. J. Elledge, Autoantigen discovery with a synthetic human peptidome. *Nat. Biotechnol.* 29, 535–541 (2011).
- 44. S. E. Vazquez, S. A. Mann, A. Bodansky, A. F. Kung, Z. Quandt, E. M. N. Ferré, N. Landegren, D. Eriksson,
 P. Bastard, S.-Y. Zhang, J. Liu, A. Mitchell, I. Proekt, D. Yu, C. Mandel-Brehm, C.-Y. Wang, B. Miao, G.
 Sowa, K. Zorn, A. Y. Chan, V. M. Tagi, C. Shimizu, A. Tremoulet, K. Lynch, M. R. Wilson, O. Kämpe, K.
 Dobbs, O. M. Delmonte, R. Bacchetta, L. D. Notarangelo, J. C. Burns, J.-L. Casanova, M. S. Lionakis, T. R.
 Torgerson, M. S. Anderson, J. L. DeRisi, Autoantibody discovery across monogenic, acquired, and COVID-19associated autoimmunity with scalable PhIP-seq. *Elife*. 11 (2022), doi:10.7554/eLife.78550.
- 1042 45. S. E. Vazquez, E. M. Ferré, D. W. Scheel, S. Sunshine, B. Miao, C. Mandel-Brehm, Z. Quandt, A. Y. Chan, M.
 1043 Cheng, M. German, M. Lionakis, J. L. DeRisi, M. S. Anderson, Identification of novel, clinically correlated
 1044 autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq. *Elife*. 9 (2020),
 1045 doi:10.7554/eLife.55053.
- 46. C. Mandel-Brehm, S. E. Vazquez, C. Liverman, M. Cheng, Z. Quandt, A. F. Kung, A. Parent, B. Miao, E.
 Disse, C. Cugnet-Anceau, S. Dalle, E. Orlova, E. Frolova, D. Alba, A. Michels, B. E. Oftedal, M. S. Lionakis,
 E. S. Husebye, A. K. Agarwal, X. Li, C. Zhu, Q. Li, E. Oral, R. Brown, M. S. Anderson, A. Garg, J. L. DeRisi,

- Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. *Diabetes*. 72, 59–70 (2023).
- 47. P. D. Burbelo, R. Castagnoli, C. Shimizu, O. M. Delmonte, K. Dobbs, V. Discepolo, A. Lo Vecchio, A.
 Guarino, F. Licciardi, U. Ramenghi, E. Rey-Jurado, C. Vial, G. L. Marseglia, A. Licari, D. Montagna, C. Rossi,
 G. A. Montealegre Sanchez, K. Barron, B. M. Warner, J. A. Chiorini, Y. Espinosa, L. Noguera, L. Dropulic, M.
 Truong, D. Gerstbacher, S. Mató, J. Kanegaye, A. H. Tremoulet, Pediatric Emergency Medicine Kawasaki
 Group, E. M. Eisenstein, H. C. Su, L. Imberti, M. C. Poli, J. C. Burns, L. D. Notarangelo, J. I. Cohen,
 Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients
 With COVID-19 and Children With MIS-C. *Front. Immunol.* 13, 841126 (2022).
- 1058 48. L. Johannes, C. Wunder, The SNXy flavours of endosomal sorting. *Nat. Cell Biol.* **13** (2011), pp. 884–886.
- 49. J. Wei, H. Lian, W. Guo, Y.-D. Chen, X.-N. Zhang, R. Zang, L. Zhong, Q. Yang, M.-M. Hu, W.-W. Luo, H.-B.
 Shu, S. Li, SNX8 modulates innate immune response to DNA virus by mediating trafficking and activation of MITA. *PLoS Pathog.* 14, e1007336 (2018).
- 1062 50. J. Wei, W. Guo, H. Lian, Q. Yang, H. Lin, S. Li, H.-B. Shu, SNX8 mediates IFNγ-triggered noncanonical signaling pathway and host defense against Listeria monocytogenes. *Proc. Natl. Acad. Sci. U. S. A.* 114, 13000–13005 (2017).
- 1065 51. C. R. Zamecnik, J. V. Rajan, K. A. Yamauchi, S. A. Mann, R. P. Loudermilk, G. M. Sowa, K. C. Zorn, B. D.
 1066 Alvarenga, C. Gaebler, M. Caskey, M. Stone, P. J. Norris, W. Gu, C. Y. Chiu, D. Ng, J. R. Byrnes, X. X. Zhou,
 1067 J. A. Wells, D. F. Robbiani, M. C. Nussenzweig, J. L. DeRisi, M. R. Wilson, ReScan, a Multiplex Diagnostic
 1068 Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. *Cell Rep Med.* 1, 100123 (2020).
- 1069 52. A. Pugliese, Autoreactive T cells in type 1 diabetes. J. Clin. Invest. 127, 2881–2891 (2017).
- J. M. Dan, C. S. Lindestam Arlehamn, D. Weiskopf, R. da Silva Antunes, C. Havenar-Daughton, S. M. Reiss,
 M. Brigger, M. Bothwell, A. Sette, S. Crotty, A Cytokine-Independent Approach To Identify Antigen-Specific
 Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. *J. Immunol.* 197, 983–993 (2016).
- 1074 54. C. Havenar-Daughton, S. M. Reiss, D. G. Carnathan, J. E. Wu, K. Kendric, A. Torrents de la Peña, S. P.
 1075 Kasturi, J. M. Dan, M. Bothwell, R. W. Sanders, B. Pulendran, G. Silvestri, S. Crotty, Cytokine-Independent
 1076 Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates
 1077 Using a Live Cell Activation-Induced Marker Technique. *J. Immunol.* **197**, 994–1002 (2016).
- 1078 55. C. Rydyznski Moderbacher, S. I. Ramirez, J. M. Dan, A. Grifoni, K. M. Hastie, D. Weiskopf, S. Belanger, R.
 1079 K. Abbott, C. Kim, J. Choi, Y. Kato, E. G. Crotty, C. Kim, S. A. Rawlings, J. Mateus, L. P. V. Tse, A. Frazier,
 1080 R. Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire, D. M. Smith, A. Sette, S. Crotty, Antigen-Specific
 1081 Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
 1082 *Cell.* 183, 996-1012.e19 (2020).
- 1083 56. R. Vita, S. Mahajan, J. A. Overton, S. K. Dhanda, S. Martini, J. R. Cantrell, D. K. Wheeler, A. Sette, B. Peters,
 1084 The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Res.* 47, D339–D343 (2019).
- 57. J. S. Lee, S. Park, H. W. Jeong, J. Y. Ahn, S. J. Choi, H. Lee, B. Choi, S. K. Nam, M. Sa, J.-S. Kwon, S. J.
 Jeong, H. K. Lee, S. H. Park, S.-H. Park, J. Y. Choi, S.-H. Kim, I. Jung, E.-C. Shin, Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. *Sci Immunol.* 5 (2020), doi:10.1126/sciimmunol.abd1554.
- S8. C. de Cevins, M. Luka, N. Smith, S. Meynier, A. Magérus, F. Carbone, V. García-Paredes, L. Barnabei, M.
 Batignes, A. Boullé, M.-C. Stolzenberg, B. P. Pérot, B. Charbit, T. Fali, V. Pirabakaran, B. Sorin, Q. Riller, G.
 Abdessalem, M. Beretta, L. Grzelak, P. Goncalves, J. P. Di Santo, H. Mouquet, O. Schwartz, M. Zarhrate, M.
 Parisot, C. Bole-Feysot, C. Masson, N. Cagnard, A. Corneau, C. Brunaud, S.-Y. Zhang, J.-L. Casanova, B.
 Bader-Meunier, J. Haroche, I. Melki, M. Lorrot, M. Oualha, F. Moulin, D. Bonnet, Z. Belhadjer, M. Leruez, S.

- Allali, C. Gras-Leguen, L. de Pontual, Pediatric-Biocovid Study Group, A. Fischer, D. Duffy, F. Rieux-Laucat,
 J. Toubiana, M. M. Ménager, A monocyte/dendritic cell molecular signature of SARS-CoV-2-related
 multisystem inflammatory syndrome in children with severe myocarditis. *Med.* 2, 1072-1092.e7 (2021).
- 1097 59. M. Miron, W. Meng, A. M. Rosenfeld, S. Dvorkin, M. M. L. Poon, N. Lam, B. V. Kumar, Y. Louzoun, E. T. Luning Prak, D. L. Farber, Maintenance of the human memory T cell repertoire by subset and tissue site.
 1099 *Genome Med.* 13, 100 (2021).
- 1100 60. HAN Archive 00432 (2021), (available at https://emergency.cdc.gov/han/2020/han00432.asp).
- E. Rackaityte, I. Proekt, H. S. Miller, A. Ramesh, J. F. Brooks, A. F. Kung, C. Mandel-Brehm, D. Yu, C.
 Zamecnik, R. Bair, S. E. Vazquez, S. Sunshine, C. L. Abram, C. A. Lowell, G. Rizzuto, M. R. Wilson, J.
 Zikherman, M. S. Anderson, J. L. DeRisi, Validation of a murine proteome-wide phage display library for the
 identification of autoantibody specificities. *bioRxiv* (2023), p. 2023.04.07.535899, ,
 doi:10.1101/2023.04.07.535899.
- 62. J. J. Sabatino Jr, K. Mittl, W. M. Rowles, K. McPolin, J. V. Rajan, M. T. Laurie, C. R. Zamecnik, R. Dandekar,
 B. D. Alvarenga, R. P. Loudermilk, C. Gerungan, C. M. Spencer, S. A. Sagan, D. G. Augusto, J. R. Alexander,
 J. L. DeRisi, J. A. Hollenbach, M. R. Wilson, S. S. Zamvil, R. Bove, Multiple sclerosis therapies differentially
 affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. *JCI Insight*. 7 (2022),
 doi:10.1172/jci.insight.156978.
- 1111 63. J. J. Sabatino Jr, M. R. Wilson, P. A. Calabresi, S. L. Hauser, J. P. Schneck, S. S. Zamvil, Anti-CD20 therapy
 1112 depletes activated myelin-specific CD8+ T cells in multiple sclerosis. *Proc. Natl. Acad. Sci. U. S. A.* 116,
 1113 25800–25807 (2019).
- 1114 64. F. A. Wolf, P. Angerer, F. J. Theis, SCANPY: large-scale single-cell gene expression data analysis. *Genome* 1115 *Biol.* 19, 15 (2018).
- A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell transcriptomic data across
 different conditions, technologies, and species. *Nat. Biotechnol.* 36, 411–420 (2018).
- 66. K. Polański, M. D. Young, Z. Miao, K. B. Meyer, S. A. Teichmann, J.-E. Park, BBKNN: fast batch alignment of single cell transcriptomes. *Bioinformatics*. 36, 964–965 (2020).
- V. A. Traag, L. Waltman, N. J. van Eck, From Louvain to Leiden: guaranteeing well-connected communities.
 Sci. Rep. 9, 5233 (2019).
- 1122 68. E. Becht, L. McInnes, J. Healy, C.-A. Dutertre, I. W. H. Kwok, L. G. Ng, F. Ginhoux, E. W. Newell,
 1123 Dimensionality reduction for visualizing single-cell data using UMAP. *Nat. Biotechnol.* (2018),
 1124 doi:10.1038/nbt.4314.
- F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R.
 Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, É. Duchesnay, Scikitlearn: Machine Learning in Python. *J. Mach. Learn. Res.* 12, 2825–2830 (2011).



(a) Design of PhIP-Seq experiment comparing MIS-C patients (n=199) and at-risk controls (n=45; children with SARS-CoV-2 infection at least 5 weeks prior to sample collection without symptoms of MIS-C). (b) Venn-diagram highlighting the number of autoantigens identified with statistically significant PhIP-Seq enrichment ('Enrichment set': Gray circle; p-value <0.01 on Kolmogorov-Smirnov (KS) test with Bonferroni FDR correction) and autoantigens identified which contribute to a logistic regression classifier of MIS-C relative to at-risk controls ('Classifier set': Purple circle). There are 35 autoantigens present in both the classifer set and enrichment set (Red; union of Venn Diagram) of which 30 are exclusive to MIS-C and referred to as the 'MIS-C Set' (no two controls have low reactivity as defined by fold change signal over mean of Protein A/G beads only (FC > mock-IP) of 3 or greater, and no single control has high reactivity defined as FC > mock-IP greater than 10). (c) Receiver operating characteristic curve for the logistic regression classifier and barplot showing autoantigens with the top 10 logistic regression coefficients. (d) Hierarchically clustered (Pearson) heatmap showing the PhIP-Seq enrichment (FC >mock-IP) for the 30 autoantigens in the MIS-C Set in each MIS-C patient and each at-risk plasma control. (e) Radioligand binding assay (RLBA) values for 196 of the 199 individuals with MIS-C and each at-risk control for each of the top 3 autoantibodies identified by PhIP-Seq logistic regression. (f) Logistic regression receiver operating characteristic curve using input RLBA values to distinguish MIS-C from at-risk controls. For the figure, Mann-Whitney U testing was performed; *****p-value < 0.00001.



Figure 2: Autoantibodies in MIS-C patients target a single epitope within SNX8.

(a) PhIP-Seq signal (reads per 100k) for each MIS-C patient (n=199) and each at-risk control (n=45) across each of the 19 bacteriophage encoded peptide fragments which together tile the full length SNX8 protein. (b) SLBA enrichments (normalized antibody indices) for each sequential alanine mutagenesis construct. Constructs were designed with 10 amino-acid alanine windows shifted by 5 amino-acids until the entire immunodominant SNX8 region (SNX8 Fragment 2) was scanned. Values are averages of 6 separate MIS-C patients. Identified autoantibody epitope bounded by vertical gray dotted lines.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.26.23290373; this version posted May 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



AAAAAAAAAATPQAIEPQAIVQQVPA PSR MQMPQG NPLLLSHTLQELLA AAAAAAAAAADHIGTRNPANNAAIV LQLPQG TTLPKGFY AEGSRGGSQA ATEGAAAAAAAAAAAAARNPANNAAIV LQLPQG TTLPKGFY AEGSRGGSQA EADPPAAAAAAAAAAEPQAIVQQVPA PSR MQMPQG NPLLLSHTLQELLA ATEGALNTPKAAAAAAAAAAAAAAAIV LQLPQG TTLPKGFY AEGSRGGSQA EADPPASDLPAAAAAAAAAAQQVPA PSR MQMPQG NPLLLSHTLQELLA ATEGALNTPKDHIGTAAAAAAAAAA LQLPQG TTLPKGFY AEGSRGGSQA EADPPASDLPTPQAIAAAAAAAAA PSR MOMPQG NPLLLSHTLQELLA ATEGALNTPKDHIGTRNPANAAAAA AAAAAG TTLPKGFY AEGSRGGSQA EADPPASDLPTPQAIEPQAIAAAAAA AAA AQMPQG NPLLLSHTLQELLA ATEGALNTPKDHIGTRNPANNAAIV AAAAAA AAAAKGFY AEGSRGGSQA EADPPASDLPTPQAIEPQAIVQQVPA AAA AAAAAA NPLLLSHTLQELLA ATEGALNTPKDHIGTRNPANNAAIV EADPPASDLPTPQAIEPQAIVQQVPA PSR MAAAAA AAAAASHTLQELLA ATEGALNTPKDHIGTRNPANNAAIV LQLPQG TTLPAAAA AAAAAAGSQA EADPPASDLPTPOAIEPOAIVOOVPA PSR MOMPOG AAAAAAAAAAAELLA ATEGALNTPKDHIGTRNPANNAAIV LQLPQG TTLPKGFY AAAAAAAAAA EADPPASDLPTPQAIEPQAIVQQVPA PSR MOMPQG NPLLLAAAAAAAA SNX8 Epitope PSRMQMPQG-

MADS Epitope ---LQLPQGTTLPKGFY

e

[ML]Q[ML]PQG Shared Epitope medRxiv preprint doi: https://doi.org/10.1101/2023.05.26.23290373; this version posted May 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license. Figure 3: MIS-C patient antibodies preferentially target distinct region of SARS-CoV-2 N protein.

(a) Relative PhIP-Seq signal (fold-change over mean of 48 pre-COVID controls (FC > Pre-COVID)) in MIS-C patients (n=181) and at-risk controls (n=45) using custom phage display library expressing entire SARS-CoV-2 proteome to different regions of SARS-CoV-2. Only regions with mean antibody signal >1.5 fold above pre-COVID controls shown. Antigenicity (sum of mean FC > pre-COVID in MIS-C and at-risk controls) represented by darker shades. Length of bars represents statistical difference in signal between MIS-C and at-risk controls to a particular region (-log 10 of Kolmogorov-Smirnov test p-values), with upward deflections representing enrichment in MIS-C versus at-risk controls, and downward deflections representing less signal in MIS-C. (b) Barplots showing PhIP-Seq signal (FC > Pre-COVID) across the specific region of the SARS-CoV-2 N protein with most divergent response in MIS-C samples relative to at-risk controls. Amino acid sequence of region with highest relative enrichment in MIS-C highlighted in green, and referred to as the MIS-C associated domain of SARS-CoV-2 (MADS). (c) Stripplots showing MADS SLBA enrichments (normalized antibody indices) in MIS-C patients (n=11) relative to at-risk controls (n=5). (d) SLBA signal (normalized antibody indices) for full sequential alanine mutagenesis scans within the same 3 individuals for SNX8 (left) and MADS (right) identification of epitopes to each (bounded by red dotted vertical lines). (e) Multiple sequence alignment of SNX8 and MADS epitopes (ClustalOmega; asterisk=identical amino acid; colon=strongly similar properties with Gonnet PAM 250 matrix score >0.5) with amino acid sequence for similarity region shown (orange). For the figure, Kolmogorov-Smirnov testing was used to compare PhIP-Seq signal, and Mann-Whitney U testing was used to compare SLBA signal; ns p-value > 0.05, **p-value < 0.01, *****p-value < 0.00001.



Figure 4: MIS-C patients harbor T-cells autoreactive to SNX8 which cross-react with SARS-CoV-2.

(a) Representative activation induced marker (AIM) assay flow cytometry gating strategy measuring percent of CD4+ T-cells which activate in response to SNX8 protein (CD137+/OX40+) and percent of CD8+ T-cells which activate (CD137+/CD69+). (b) Barplot showing distribution of T-cells which activate in response to either vehicle (culture media + 0.2% DMSO) or SNX8 peptide pool (SNX8 peptide + culture media + 0.2% DMSO). (c) Gating strategy used to identify CD8+ T-cells which bound to SNX8 epitope and/or MADS N protein epitope (CD8+ T-cells positive for PE). Representative MIS-C patient and control showing each CD8+ T-cell which bound to any tetramer (PE+) and the relative binding of that T-cell to both the SNX8 epitope (BV421+) and the MADS N protein epitope (APC+) identifying cross-reactive T-cells (PE+/APC+/BV421+). (d) Barplot showing percentage of CD8+ T-cells which are cross-reactive to both SNX8 and MADS in MIS-C and controls (3 MIS-C patients and 3 at-risk controls). For the figure, Mann-Whitney U testing was performed; ***p-value <0.001.



Supplemental Figure 1: Previously reported MIS-C associated autoantigens.

(a) Heatmap showing distribution of PhIP-Seq enrichments (FC > Mock-IP) of previously reported MIS-C autoantibodies in MIS-C patients (n=199) and at-risk controls (n=45). (b) Stripplots showing distribution of signal (normalized antibody index) for antibodies targeting IL-1 receptor antagonist (IL-1Ra) measured by RLBA in at-risk controls (blue; n=45), MIS-C patient samples containing IVIG (red; n=135), and MIS-C patient samples without IVIG (green; n=61). Dotted line at 3 standard deviations above the mean of controls. For the figure, Mann-Whitney U testing was performed; ns p-value > 0.05, ****p-value < 0.0001, *****p-value < 0.00001.



Supplemental Figure 2: Absence of tissue specific autoantibodies correlating to phenotypes.

Heatmap of p-values (Kolmogorov-Smirnov testing) for differences in autoantibody enrichment for MIS-C patients with versus without each clinical phenotype. Significant p-values in the negative direction (in which there is increased signal in individuals without the phenotype) are masked (colored as p > 0.05). For each autoantigen, tissue RNA-sequencing data from Human Protein Atlas (Proteinatlas.org) is shown. Amount of expression in cardiac tissue in top row (Very high=nTPM >1000, High=nTPM 100-1000, Moderate=nTPM 10-100, Low=nTPM <10), and predominant tissue type in second-from-top row. Explanations of criteria for MIS-C phenotypes, and distribution of each phenotype within the cohort, can be found in Supplemental Table 1.



Supplemental Figure 3: Significantly increased autoantibodies is MIS-C samples without IVIG.

(a) Stripplots showing RLBA enrichments (normalized antibody indices) in samples containing IVIG (green) and samples without IVIG (magenta) for ERFL, SNX8, and KDELR1 in MIS-C patients (n=196) and at-risk controls (n=45). (b) Stripplots showing RLBA enrichment only in those MIS-C samples without IVIG (n=62) relative to at-risk controls (n=45). For the figure, Mann-Whitney U testing was performed; ***p-value < 0.001, ****p-value < 0.0001, ****p-value < 0.0001.





Supplemental Figure 4: Validation of autoantibody classifier using independent MIS-C cohort. (a) Stripplots showing RLBA enrichments (normalized antibody indices) for ERFL, SNX8, and KDELR1 in an independent cohort of children with MIS-C (red; n=24) compared to children severely ill with acute COVID-19 (yellow; n=29) and at-risk controls (blue; n=45) (b) Logistic regression receiver operating characteristic curves for classification of the independent MIS-C cohort versus at-risk controls (left) and the independent MIS-C cohort versus children severely ill with acute COVID-19 (right). For the figure, Mann-Whitney U testing was performed; ns p-value > 0.05, *p-value < 0.05, *p-value < 0.01, ***p-value < 0.001, ***p-value < 0.001.



SNX8 WT fragment O SNX8 epitope mutagenesis

Supplemental Figure 5: Prevalence of epitope specific SNX8 autoantibodies in MIS-C and controls. Paired stripplots showing SLBA enrichments (normalized antibody indices) in MIS-C patients (n=182) and at-risk controls (n=45) for the full 49 amino acid SNX8 wild-type (WT) polypeptide fragment (lavender) relative to the same SNX8 fragment with alanine mutagenesis of the [PSRMQMPQG] epitope (white). SNX8 WT fragment SLBA values are the means of technical replicates, SNX8 epitope mutagenesis values are from a single experiment. For the figure, Mann-Whitney U testing was performed; ns p-value > 0.05, ****p-value < 0.0001.



Supplemental Figure 6: Activation of CD4+ and CD8+ T-cells with associated HLA type.

Stripplots showing distribution of CD4+, CD8+, and total T-cells which activate in response to either vehicle (culture media + 0.2% DMSO) or SNX8 peptide pool (SNX8 peptide + culture media + 0.2% DMSO) using AIM assay. HLA type indicated by color of dot. HLA unpredicted means patient contained none of the MIS-C associated HLA types. Dotted line at 3 standard deviations above the mean of the SNX8 stimulated controls. For the figure, Mann-Whitney U testing was performed; ***p-value <0.001.



Supplemental Figure 7: HLA-A*02 preferentially displays MADS and SNX8 similarity regions on MHC1. (a) Computationally predicted MHCI presentation scores (Immune Epitope Database; IEDB.org) for each possible peptide fragment of full length SARS-CoV-2 N protein for each of the three MIS-C associated HLA types (A*02, B*35 and C*04) relative to a reference set of HLA-types encompassing over 99% of humans. Those fragments containing the MADS similarity region "LQLPQG" in orange. Percent of fragments within each specific HLA sub-type with a score greater than 0.1 (likely to be presented) shown on right. (b) Identical analysis but using full length SNX8 protein rather than SARS-CoV-2 NP, and the SNX8 similarity region "MGMPQG" rather than the MADS region "LQLPQG". For the figure, the peptide MHCI presentation scores for all peptides within an HLA type were normally distributed, so a t-test was used to compare signal. ns p-value > 0.05, ***p-value <0.001, ****p-value < 0.001.

T-cell Activation to SNX8 Epitope



Supplemental Figure 8: Stimulation with SNX8 epitope only is sufficient to activate T-cells in MIS-C patients.

Stripplots showing percentage of total T-cells which activate in response to either vehicle (culture media + 0.2% DMSO) or the SNX8 Epitope (SNX8 Epitope (Materials) + culture media + 0.2% DMSO) in MIS-C patients (n=2) and at-risk controls (n=4) measured by AIM assay. Dotted line at 3 standard deviations above mean of SNX8 Epitope stimulated controls.



Supplemental Figure 9: SNX8 expression during viral infection.

(a) UMAPs showing SNX8 expression in various peripheral blood cell types during SARS-CoV-2 infection. (b) Mean expression and percent of cells expressing SNX8 in peripheral blood subsets during SARS- CoV-2 infection. (c) Mean expression and percent of cells expressing SNX8 averaged across all peripheral blood mononuclear cells from SARS-CoV-2 infected individuals without symptoms, with mild symptoms, or with severe disease compared to uninfected controls. (d) Mean expression and percent of cells expressing SNX8, OAS1, OAS2, and MAVS in peripheral blood subsets during SARS-CoV-2 infection. (e) Relative expression of SNX8, OAS1, OAS2, and MAVS during influenza infection compared to different severities of SARS-CoV-2 infection.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.26.23290373; this version posted May 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



Supplemental Figure 10: Representative flow cytometry for AIM, tetramer, and serotyping experiments.

(a) FlowJo plots showing gating strategy for identifying CD4 positive and CD8 positive T-cells for the AIM analysis shown in Figure 4. (b) FlowJo gating strategy for the tetramer assay showing isolation of PE-tetramer positive CD8 positive T-cells. (c) FlowJo plots showing results of serotyping for the PBMCs used in the SNX8/MADS tetramer cross-reactivity assay which did not have sufficient cells for genotyping. Shown is the 1 MIS-C patient (far left) and 3 controls (middle 3) which are positive for HLA-A*02 and were used in the tetramer cross-reactivity assay, and one control negative for HLA-A*02 (far right) which was not used.